



## 31 SHORT ABSTRACT

32 Epidemiologic risk factors for incident SARS-CoV-2 infection are best characterized via  
33 prospective cohort studies, complementing case-based surveillance and cross-sectional  
34 seroprevalence studies. In March 2020, we launched the CHASING COVID Cohort Study, a  
35 national, community-based prospective cohort study of 6,745 U.S. adults who underwent at-  
36 home specimen collection for repeat serologic testing for SARS-CoV-2 antibodies. We identify  
37 and quantify several policy-sensitive risk factors for recent SARS-CoV-2 seroconversion,  
38 highlight persistent racial/ethnic disparities in incidence, document continued elevated risk  
39 among essential workers, and call attention to major gaps in the coverage of public health  
40 interventions aimed at testing, isolation, and contact tracing. We conclude that modifiable risk  
41 factors and poor reach of public health strategies drive SARS-CoV-2 transmission and inequities  
42 across the U.S.

43

## 44 LONG ABSTRACT

### 45 Background

46 Epidemiologic risk factors for incident SARS-CoV-2 infection are best characterized via  
47 prospective cohort studies, complementing case-based surveillance and cross-sectional  
48 seroprevalence studies.

49

### 50 Methods

51 We estimated the cumulative incidence of SARS-CoV-2 infection and incidence rates of  
52 seroconversion in a national prospective online cohort of 6,745 U.S. adults, enrolled March-July  
53 2020. A subset (n=4,459) underwent serologic testing (Bio-Rad Platelia Total Ab,  
54 IgA/IgM/IgG), offered initially May-September 2020 and again November 2020-January 2021.

55

### 56 Results

57 A total of 303 of 4,459 individuals showed serologic evidence of past SARS-CoV-2 infection  
58 (cumulative incidence of 6.8%; 95% Confidence Interval [CI] 6.1%-7.6% [6.3%, 95% CI 5.7%-  
59 7.1% adjusting for laboratory test error]). Among 3,280 initially seronegative participants with a  
60 subsequent serologic test, we observed 145 seroconversions during 1,562 person years of follow-  
61 up (incidence rate of 9.3 per 100 person-years [95% CI 17.9-11.0]). Racial/ethnic disparities in  
62 crude incidence rates were apparent through January 2021 (rate ratio [RR]<sub>Hispanic vs Whites</sub>=2.1;  
63 95% CI 1.4-3.1; RR<sub>non-Hispanic Blacks vs Whites</sub>=1.8; 95% CI 0.96-3.1). Incidence was higher in the  
64 southern (RR<sub>South vs Northeast</sub>=1.7; 95% CI 1.1-2.8) and midwestern (RR<sub>Midwest vs Northeast</sub>=1.6; 95%  
65 CI 0.98-2.7) regions, in rural vs urban areas (RR=1.5; 95% CI 1.0-2.2), and among essential  
66 workers (RR=1.7; 95% CI 1.1-2.5). Household crowding (RR=1.6, 95% CI 1.1-2.3), dining  
67 indoors at restaurants/bars (RR=2.0; 95% CI 1.4-2.8), visiting places of worship (RR=2.0; 95%  
68 CI 1.3-2.9), wearing masks sometimes vs always while grocery shopping (RR=2.5; 95% CI 1.3-  
69 4.4), indoor visits with people outside the household with masks (RR<sub>always mask vs no visit</sub>=2.6; 95%  
70 CI 1.6-4.4) and without masks (RR<sub>sometimes mask vs no visit</sub>=3.5; 95% CI 2.7-5.7; RR<sub>never mask vs no</sub>  
71 visit=5.3; 95% CI 3.1-8.9); working indoors at a place of employment with masks (RR<sub>always mask vs</sub>  
72 no in-person=2.0, 95% CI 1.4-2.8) and without masks (RR<sub>sometimes mask vs no in-person</sub>= 2.0, 95% CI 1.1-

73 3.5;  $RR_{\text{never mask vs no in-person}}=3.7$ , 95% CI 1.3-8.5); attending a salon or gym with masks ( $RR_{\text{always}}$   
74  $\text{mask vs no salon/gym}=1.7$  (95% CI 1.1-2.4), gathering indoors and outdoors in groups of  $\geq 10$  ( $RR=1.9$ ,  
75 95% CI 1.2-2.0); and air travel during the pandemic ( $RR=1.7$ ; 95% CI 1.1-2.6) were also  
76 associated with higher incidence rates. Among 303 seropositive individuals, 27.4% had  
77 asymptomatic infection, and 32% reported a positive SARS-CoV-2 PCR test or provider  
78 diagnosis of COVID-19. In this group, there were major gaps in the coverage of public health  
79 interventions aimed at isolation (31% isolated) and contact tracing (asked about contacts [18%];  
80 told about exposure to a confirmed case [7.6%]).

81  
82 **Conclusions**  
83 Modifiable risk factors and low reach of public health strategies drive SARS-CoV-2 transmission  
84 across the U.S. It is critical to address inequities in incidence, reduce risk factors, and improve  
85 the reach of public health strategies in the vaccine era.

86  
87 **KEYWORDS:** COVID-19; serology, seroconversion, asymptomatic infection, physical  
88 distancing; natural history study, epidemiologic study, essential workers, public health  
89 interventions, community transmission

90  
91

## 92 INTRODUCTION

93 As of this writing, about one year after the emergence of SARS-CoV-2 in the United States  
94 (U.S.), there have been more than 25 million SARS-CoV-2 cases diagnosed, 435,000 deaths  
95 recorded, and 23.5 million vaccine doses administered.<sup>1</sup> As compared to *diagnoses*, the true  
96 number of *infections* to date in the U.S. is unknown, but national estimates in the general  
97 population as measured by seroprevalence have put the cumulative incidence at 10% in  
98 September 2020<sup>2</sup> and 14% as of November 2020.<sup>3</sup> One recent study in a nationally  
99 representative sample of U.S. adults found that 4.6% had a history of undiagnosed SARS-CoV-2  
100 as of July 2020: about 5 undiagnosed infections for every diagnosed case.<sup>4</sup>

101 A major challenge of controlling community transmission of SARS-CoV-2 is that the virus'  
102 infectious period allows for onward spread prior to recognition of infection, by the substantial  
103 proportion of people with asymptomatic infection, and during the pre-symptomatic period among  
104 those who go on to develop symptoms.<sup>4,5</sup>

105 While SARS-CoV-2 is understood to be transmitted from person-to-person via droplet and  
106 airborne spread, to date, the incidence of SARS-CoV-2 infection and risk factors for incident  
107 infection have not been well-characterized by routine case-based surveillance of SARS-CoV-2  
108 diagnoses or by cross-sectional seroprevalence studies.<sup>1-3</sup> As the pandemic progresses through  
109 different seasons and stages, it is critical to continue to characterize COVID-19's evolving  
110 epidemiology and risk factors for SARS-CoV-2 acquisition, the uptake and impact of non-  
111 pharmaceutical interventions (NPIs)<sup>6</sup>, and the reach of public health strategies aimed at  
112 controlling community transmission, including testing, quarantine, isolation, contact tracing, and  
113 vaccination.

114 Researchers and public health practitioners have called for prospective cohort studies to  
115 describe incidence rates and how they are influenced by NPI implementation and uptake,  
116 sociodemographics, knowledge and behaviors, and other potential risk factors.<sup>7</sup> Yet, both the  
117 frequency with which many risk factors occur in community samples, as well as the SARS-CoV-  
118 2 risk that could be attached to them, still have not been systematically assessed and  
119 epidemiologically linked to outcomes like seroconversion. Globally, few prospective  
120 epidemiologic studies of SARS-CoV-2 have been published to date. One recent global  
121 systematic review of observational studies of SARS-CoV-2 that employed serologic or PCR  
122 testing found 18 prospective studies.<sup>8</sup> Most were focused on healthcare workers or other

123 occupational groups, individuals in congregate settings, evacuees, or cruise ships; none were  
124 community-based (i.e., focused on risk factors in communities vs other higher risk  
125 populations/settings).<sup>8</sup> A greater understanding of SARS-CoV-2 incidence and risk factors in  
126 community samples can substantially complement routine case-based surveillance of new SARS-  
127 CoV-2 diagnoses and cross-sectional serosurveys, serving to inform aspects of implementation  
128 of the public health response and policies.

129 In late March 2020, we launched the national, prospective Communities, Households and  
130 SARS-CoV-2 Epidemiology (CHASING) COVID Cohort.<sup>9</sup> We describe the cumulative  
131 incidence of SARS-CoV-2 infection, risk factors for recent SARS-CoV-2 seroconversion, and,  
132 for those with serologic evidence of prior SARS-CoV-2 infection, the reach and uptake of public  
133 health strategies.

134

## 135 **METHODS**

136 We used internet-based strategies<sup>10-12</sup> to recruit a geographically and socio-demographically  
137 diverse cohort of adults in the U.S. and U.S. territories into longitudinal follow-up with at-home  
138 specimen collection. To be eligible for inclusion in the cohort, individuals had to: 1) reside in the  
139 U.S. or a U.S. territory; 2) be aged 18 years or older; 3) provide a valid email address for follow-  
140 up; and 4) demonstrate early engagement in study activities (provided a baseline specimen or  
141 completed >1 recruitment/enrollment visits). Details of the study design and recruitment  
142 procedures have been described previously.<sup>9</sup>

143

### 144 **Study measurements**

145 *Participant interviews.* Measures included on the cohort screening, enrollment and follow-up  
146 questionnaires were derived from published research<sup>10</sup>, BRFSS<sup>13</sup>, 2009 H1N1 influenza  
147 studies<sup>14,15</sup>, and other COVID-19 studies.<sup>16</sup> Measures were also developed *de novo*. Cohort  
148 recruitment and enrollment visits were completed between March 28-August 21, 2020, during  
149 which multiple rounds of interviews took place. Essential worker status was defined as working  
150 in law enforcement, emergency management, delivery, transportation, construction or healthcare  
151 at study enrollment. We separated healthcare workers from other essential workers and treated  
152 them as distinct categories in our analyses. From follow-up interviews we obtained repeated

153 measurements of symptoms, testing, hospitalizations, quarantine, isolation, contact tracing  
154 encounters, and other time-varying factors.

155 *At-home specimen collection for serologic testing.* As part of study assessments during  
156 May-August 2020 (Period 1) and November 2020-January 2021 (Period 2), participants were  
157 invited to participate in serologic testing using an at-home self-collected dried blood spot (DBS)  
158 specimen collection kit. Consenting participants were mailed a specimen collection kit, which  
159 included written instructions and a QR code for an instructional video. DBS cards were sent from  
160 and returned to the study laboratory (Molecular Testing Laboratories [MTL], Vancouver,  
161 Washington) via the U.S. Postal Service (self-addressed, stamped envelope containing a  
162 biohazard bag™).

163 *Serologic testing.* All DBS specimens were tested by the study laboratory for total  
164 antibodies (Total Ab) using the Bio-Rad Platelia test for IgA, IgM, and IgG which targets the  
165 SARS-CoV-2 nucleocapsid protein (manufacturer sensitivity 98.0%, specificity 99.3%).<sup>17</sup>  
166 Specimens that were reactive on the Total Ab test were tested further using the Euroimmun IgG  
167 test which targets the SARS-CoV-2 spike protein (manufacturer sensitivity 100%; specificity  
168 99%).<sup>17</sup> Both assays received Emergency Use Authorization from the U.S. Food and Drug  
169 Administration and were further validated for use with DBS by the study laboratory using  
170 confirmed, true positive and negative patient specimens. In these local validations, both assays  
171 were found to have 100% sensitivity and 100% specificity (MTL, personal communication).

172 *Cumulative incidence of SARS-CoV-2 infection.* Among participants who underwent  
173 serologic testing, we estimated the cumulative incidence of SARS-CoV-2 as the proportion of  
174 individuals with a positive Total Ab test in either of the two time periods (i.e., number of  
175 participants ever-positive) divided by the total number of persons with one or more Total Ab  
176 tests (i.e., number of participants ever tested). We adjusted cumulative incidence estimates for  
177 laboratory test error as reported by the kit manufacturer. Crude cumulative incidence estimates  
178 are presented alongside adjusted estimates in supplemental tables. Unless otherwise specified, all  
179 cumulative incidence estimates presented are adjusted for laboratory test error using the  
180 following formula<sup>18</sup>:

$$\text{Adjusted cumulative incidence} = \frac{\text{Crude cumulative incidence} + \text{Specificity} - 1}{\text{Sensitivity} + \text{Specificity} - 1}$$

182 *Observed SARS-CoV-2 seroconversion and seroreversion.* Among those individuals with  
183 two Total Ab tests, an observed seroconversion was defined as a negative Total Ab test in Period  
184 1 followed by a positive Total Ab test in Period 2. We estimated the rate of seroconversion per  
185 100 person years of follow-up using the collection dates for each specimen. Person-time at risk  
186 began at the time of dried blood spot sample collection for the first serologic test or date the lab  
187 received the sample if collection date was missing. The seroconversion date was assigned as the  
188 midpoint between the first and second sample collection dates. Observed seroreversion was  
189 defined as a positive Total Ab test in Period 1 followed by a negative Total Ab test in Period 2.

190

### 191 **Statistical analysis**

192 Cumulative incidence estimates and 95% confidence intervals (95% CIs) were stratified by  
193 enrollment characteristics and risk factors ascertained prior to specimen collection. Incidence  
194 proportions (observed seroconversions) were also stratified by risk factors measured prior to the  
195 date of specimen collection in Period 2. All data were cleaned and analyzed in R (version 4.0.3)  
196 and SAS (V9.4). Data were geocoded based on a self-reported ZIP code, and maps were created  
197 in ArcGIS 10.7. For categorical variables with missing data frequency <5%, we imputed missing  
198 data for participants using the most common value among all participants for a given variable.

199

### 200 **Ethical Approval**

201 The study protocol was approved by the Institutional Review Board at the City University of  
202 New York (CUNY) Graduate School for Public Health and Health Policy.

203

### 204 **RESULTS**

205 The characteristics of the cohort are shown in Table 1, which includes participants from all 50  
206 U.S. states, the District of Columbia, Puerto Rico, and Guam (see Fig. S1). Of the 6,745  
207 participants enrolled in the cohort, 4,459 (66%) had at least one serologic test (Table 1).

208 Compared with the entire cohort, those who underwent any serologic testing were older and  
209 more likely to be non-Hispanic White, college educated, and less likely to be healthcare workers  
210 or essential workers. 4,235 persons underwent serologic testing in Period 1, and 3,615 persons  
211 tested in Period 2. A total of 3,339 persons tested at both time points, including 3,280 who were  
212 seronegative on their antibody test in Period 1 and who could be followed prospectively for the



213 outcome of SARS-CoV-2 seroconversion based on their subsequent serologic test result in the  
 214 study. Differences between those testing in Period 1 and Period 2 were negligible (Table S1).  
 215 The median time between specimen collection dates for both serologic tests was 190 days (IQR  
 216 152-201) (Figure S2).  
 217

Table 1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants

|                        | All participants |       | Participants with one or more serologic test |      |
|------------------------|------------------|-------|--|------|
|                        | N                | %     | N  | %    |
| <b>Total</b>           | 6,745            | 100%  | 4459   | 66%  |
| <b>Age*</b>            |                  |       |  |      |
| Median (IQR)           | 37 (29,51)       |       | 41 (31, 55)                                  |      |
| 18-29                  | 1804             | 26.75 | 861  | 19.3 |
| 30-39                  | 1965             | 29.13 | 1246   | 27.9 |
| 40-49                  | 1160             | 17.2  | 846  | 19.0 |
| 50-59                  | 792              | 11.74 | 646  | 14.5 |
| 60+                    | 1024             | 15.18 | 860  | 19.3 |
| <b>Gender</b>          |                  |       |  |      |
| Male                   | 3047             | 45.17 | 1991   | 44.7 |
| Female                 | 3527             | 52.29 | 2337   | 52.4 |
| Non-Binary/Transgender | 171              | 2.54  | 131  | 2.9  |
| <b>Race/Ethnicity*</b> |                  |       |  |      |
| White Non-Hispanic     | 3859             | 56.8  | 2953   | 66.3 |
| Hispanic               | 1310             | 19.42 | 669  | 15.0 |
| Black Non-Hispanic     | 851              | 12.62 | 369  | 8.3  |
| Asian                  | 439              | 6.51  | 283  | 6.3  |
| Pacific Islander       | 36               | 0.53  | 18   | 0.4  |
| Other                  | 250              | 3.71  | 167  | 3.8  |
| <b>Education</b>       |                  |       |  |      |
| Less than high school  | 123              | 1.82  | 52   | 1.2  |
| High school graduate   | 879              | 13.03 | 399  | 9.0  |
| Some college           | 1889             | 28.01 | 1126   | 25.3 |




|                                       |      |       |      |      |
|---------------------------------------|------|-------|------|------|
| College graduate                      | 3854 | 57.14 | 2882 | 64.6 |
| <b>Employment*</b>                    |      |       |      |      |
| Employed                              | 4249 | 62.99 | 2741 | 61.5 |
| Out of work                           | 830  | 12.31 | 535  | 12.0 |
| Homemaker                             | 352  | 5.22  | 240  | 5.4  |
| Student                               | 610  | 9.04  | 362  | 8.1  |
| Retired                               | 704  | 10.44 | 581  | 13.0 |
| <b>Household income*</b>              |      |       |      |      |
| Less than \$35,000                    | 2180 | 32.32 | 1288 | 28.9 |
| \$35-49,999                           | 753  | 11.16 | 487  | 10.9 |
| \$50-69,999                           | 960  | 14.23 | 635  | 14.2 |
| \$70-99,999                           | 1058 | 15.69 | 734  | 16.5 |
| \$100,000+                            | 1794 | 26.6  | 1315 | 29.5 |
| <b>Setting*</b>                       |      |       |      |      |
| Urban                                 | 2974 | 44.09 | 1962 | 44.0 |
| Suburban                              | 1760 | 26.09 | 1143 | 25.6 |
| Rural                                 | 2011 | 29.81 | 1354 | 30.4 |
| <b>Geographic region*</b>             |      |       |      |      |
| Northeast                             | 1882 | 27.9  | 1294 | 29.0 |
| Midwest                               | 1127 | 16.71 | 794  | 17.8 |
| South                                 | 2103 | 31.18 | 1269 | 28.5 |
| West                                  | 1625 | 24.09 | 1097 | 24.6 |
| US Dependent Territories              | 8    | 0.12  | 5    | 0.1  |
| <b>Healthcare worker*</b>             |      |       |      |      |
| No                                    | 5948 | 88.18 | 4042 | 90.7 |
| Yes                                   | 797  | 11.82 | 417  | 9.4  |
| <b>Essential worker</b>               |      |       |      |      |
| No                                    | 5601 | 83    | 3858 | 86.5 |
| Yes                                   | 1144 | 17    | 601  | 13.5 |
| <b>Higher risk for severe COVID**</b> |      |       |      |      |
| No                                    | 3167 | 46.95 | 2074 | 46.5 |
| Yes                                   | 3578 | 53.05 | 2385 | 53.5 |

\*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable


\*\* >60 years old, or reported co-morbidity, or current smoker.

219 **Cumulative incidence since the beginning of the pandemic and potential risk factors**  
 220 The crude and adjusted serology-based estimates of cumulative incidence of SARS-CoV-2  
 221 infection through the end of observation (January 31, 2021) were 6.8% (95% CI 6.1%-7.6%) and  
 222 6.3% (95% CI 5.5%-7.1%), respectively (Table S2). Cumulative incidence rates declined in  
 223 dose-response fashion with increasing age, with substantially lower incidence in those aged 60  
 224 years and older (Figure 1). Higher cumulative incidence estimates were observed among males  
 225 (7.8%, 95% CI 6.6%-9.0%), Hispanics 10.2% (95% CI 7.8%-12.6%), non-Hispanic Blacks  
 226 (7.9%, 95% CI 5%-10.8%), those with a high school education (9.1%, 95% CI 0.9-20.9) or less  
 227 (8.0%, 95% CI 5.2-10.9%), and those in the Northeast (7.8%, 95% CI 6.3%-9.4%). Lower  
 228 cumulative incidence estimates were observed among persons aged 60 years and over (3.8%,  
 229 95% CI 2.5%-5.2%), those whose gender identity was non-binary (2.5%, 95% CI 0.4%-5.5%),  
 230 and those who were retired (3.4%, 95% CI 1.7%-4.9%).  
 231



232  
 233 **Figure 1** shows cumulative incidence estimates and 95% confidence intervals (CIs) for SARS-CoV-2 by baseline demographic characteristics of  
 234 CHASING COVID Cohort Study participants. Estimates are adjusted for laboratory test error. Essential workers include people working in in law  
 235 enforcement, emergency management, delivery, transportation, and construction. High risk group is defined as participants who either reported a  
 236 comorbidity, were over 60 years old, or were a smoker. The size of the square box/marker is proportional to the overall sample size in each group.  
 237

238 The estimated cumulative incidence of SARS-CoV-2 infection by epidemiologic risk factors  
 239 reported at enrollment are shown in Figure 2 (and in Table S3). Higher cumulative incidence  
 240 estimates were observed among those who, at cohort enrollment, reported having attended mass  
 241 gatherings (8.6%, 95% CI 5.8%-12.4%), and lived in more crowded households (8.7%, 95% CI  
 242 5.7%-13.2%). Those who thought they had COVID-19 in the past, and in Period 2, those who  
 243 had a known SARS-CoV-2 exposure, sought a test, had a self-reported SARS-CoV-2 diagnosis  
 244 or COVID-19-related hospitalization also had markedly higher cumulative incidence (Table S3).  
 245 People living with HIV had the highest cumulative incidence among those with comorbidities  
 246 (8.8%, 95% CI 5.5%-13.6%) over the entire study period, however, those with diabetes had the  
 247 highest cumulative incidence in Period 2 (Table S3). In terms of other potential risk factors,  
 248 those who reported recently drinking more than 6 alcoholic drinks on one occasion (9.9%, 95%  
 249 CI 6.6%-14.3%) and those who used public transportation (8.6%, 95% CI 5.7%-12.6%) had  
 250 higher cumulative incidence (Fig. 2, Table S3). Lower cumulative incidence was observed  
 251 among those who, at enrollment, reported having asthma, immunosuppression, and depression.  
 252




253  
 254 **Figure 2** shows cumulative incidence estimates and 95% confidence intervals (CIs) for SARS-CoV-2 in CHASING COVID Cohort Study participants by  
 255 risk factors. Estimates are adjusted for laboratory test kit error. All risk factors were measured at the baseline survey. Alcohol use is defined as having

256 more than 6 drinks on one occasion weekly, daily, or almost daily. (NPIs: Non-pharmaceutical interventions; HH: Household). The size of the square  
 257 box/marker is proportional to the overall sample size in each group.

258

### 259 Incidence of recent SARS-CoV-2 seroconversion and potential risk factors

260 Figure 3 (and Table S4) shows more recent seroconversions and incidence rates among 3,280  
 261 initially seronegative persons who had a subsequent serologic test during November 2020-  
 262 January 2021 (Fig. S2), stratified by risk factors that were present prior to or between serologic  
 263 tests. There were 145 observed seroconversions over 1,562 person years of follow-up among the  
 264 3,280 participants, for an overall incidence rate of 9.3 per 100 person years (PY) (95% CI 7.9-  
 265 11.0). The rate ratio (RR) for incident SARS-CoV-2 infection was higher for males than females  
 266 (RR: 1.34, 95% CI 0.96-1.87), Hispanics (RR: 2.11, 95% CI 1.40-3.12) and non-Hispanic Blacks  
 267 (RR 1.79, 95% CI 0.96-3.13) compared with non-Hispanic Whites. In contrast to cumulative  
 268 incidence estimates, incidence rates reflecting more recent seroconversions were higher among  
 269 those in rural versus urban areas (RR 1.52, 95% CI 1.04-2.22), those in the Midwest (RR 1.62,  
 270 95% CI 0.98-2.69), the South (RR 1.73, 95% CI 1.1-2.75), and the West (RR 1.34, 95% CI 0.79-  
 271 2.2) compared to the Northeast. Of note, essential workers had higher incidence than non-  
 272 essential workers (RR 1.65, 95% CI 1.09--2.46).




273

274 **Figure 3** shows risk ratio estimates and 95% confidence intervals (CIs) for recent SARS-CoV-2 seroconversion (May 2020-January 2021) in CHASING  
275 COVID Cohort Study participants by demographic factors. Essential workers include people working in law enforcement, emergency management,  
276 delivery, transportation, and construction. High risk group is defined as participants who either reported a comorbidity, were over 60 years old, or were  
277 a smoker. The size of the square box/marker is proportional to the overall sample size in each group.

278

279 Figure 4 (and Table S5) shows recent seroconversions and incidence rates for epidemiologic  
280 risk factors. Living in more crowded households was associated with higher incidence than  
281 living in less crowded households (RR 1.61, 95% CI 1.08-2.32). Compared with referent groups  
282 in Figure 4, there was also higher incidence among those who dined indoors at restaurants/bars  
283 (RR 1.95, 95% CI 1.38-2.83); those who visited a place of worship (RR 1.95, 95% CI 1.25-2.93);  
284 those who wore a mask only sometimes while grocery shopping (RR 2.49, 95% CI 1.31-4.36);  
285 those who visited indoors with people not in their own household while always wearing a mask  
286 (RR=2.6; 95% CI 1.6-4.4), while sometimes wearing a mask (RR=3.5; 95% CI 2.7-5.7 or while  
287 never wearing a mask (RR=5.3; 95% CI 3.1-8.9); those working indoors at a place of  
288 employment while always wearing a mask (RR=2.0, 95% CI 1.4-2.8), while sometimes wearing  
289 a mask (RR=2.0, 95% CI 1.1-3.5), or while never wearing a mask RR=3.7, 95% CI 1.3-8.5);  
290 those attending a salon or gym with masks (RR=1.7, 95% CI 1.1-2.4); those who gathered  
291 indoors and outdoors in groups of >10 (RR=1.9, 95% CI 1.2-2.0); and those that traveled by air  
292 during the pandemic (RR 1.72, 95% CI 1.12-2.55).

293



294

295 **Figure 4** shows risk ratio estimates and 95% confidence intervals (CIs) for recent SARS-CoV-2 seroconversion (May 2020-January 2021) in CHASING  
 296 COVID Cohort Study participants by behavioral risk factors. For indoor mask use behavior, participants that did not engage in the respective behaviors  
 297 were classified as N/A. The size of the square box/marker is proportional to the overall sample size in each group.

298

## 299 **Clinical and public health outcomes among persons with serologic evidence of SARS-CoV-** 300 **2 infection**

301 Among the 303 individuals who were positive for Total Ab during the study, only 121 (39.9%)  
 302 were aware that they had a prior SARS-CoV-2 infection (Table S6). A substantial proportion of  
 303 the 303 (27.4%) recalled no symptoms of COVID-like illness (i.e., were asymptomatic cases).  
 304 Among the 145 more recent seroconverters in Period 2, the proportion reporting no symptoms  
 305 was 25.5%, and another 60% reported milder symptoms that did not result in seeking care.

306 In terms of public health outcomes, 64.4% (195/303) said that they were tested for SARS-  
 307 CoV-2 outside the study (Table S6), half of them (32% of total) reported having a positive  
 308 SARS-CoV-2 test. However, only 30.7% of all 303 seropositives said that they had isolated  
 309 themselves from people outside their household because of their infection, and, among those  
 310 who did not live alone, even fewer (13.5% overall) said they isolated themselves from others  
 311 within their household. In terms of contact tracing, 17.8% of all seropositives were asked about

312 contacts following diagnosis and only 12.2% of all seropositives had been informed by a contact  
313 tracer that they may have had contact with someone confirmed to have SARS-CoV-2. Only 5.3%  
314 of those diagnosed (3.3% of all seropositives) were told by a contact tracer to stay home for a  
315 period of time because they had COVID-19.

316

### 317 **Repeat serologic testing outcomes**

318 A total of 303 persons who were ever seropositive by the Total Ab test contributed 392  
319 seropositive Total Ab test results over the course of the study (Table S7). This included 134  
320 persons with a positive Total Ab test in Period 1 and 258 in Period 2. Of the 258 Total Ab  
321 positives in Period 2, 145 were recent seroconverters. There were 20 individuals who were Total  
322 Ab positive in Period 1 but Total Ab negative in Period 2 (i.e., seroreverters and/or false  
323 positives). Specifically, of 134 persons who tested Total Ab positive in Period 1 and had a  
324 second test in Period 2, only 114 (85%) were still seropositive in Period 2. The median time  
325 between specimen collection for these 20 individuals was 197 days (IQR 187-201 days). Of the  
326 392 specimens that were positive on the Total Ab test from Period 1 or 2, 361 had sufficient  
327 specimen quantity for further testing. Of these, 63.4% (201/361) were also positive on the spike  
328 protein-based IgG test, including 65.7% (88/127) in Period 1, and 42.1% (113/234) in Period 2  
329 (Table S7).

330

## 331 **DISCUSSION**

332 We report findings from one of the first community-based prospective epidemiologic studies  
333 of SARS-CoV-2 incidence and risk factors, globally. We have prospectively characterized the  
334 risk of incident SARS-CoV-2 infection in relation to a range of modifiable risk factors in the  
335 U.S., using information on both past infection and recent seroconversion. With a well-  
336 characterized sample of participants with evidence of prior infection, our study suggests that  
337 public health strategies being widely used with the aim of reducing onward transmission  
338 (quarantine, testing, isolation, and contact tracing) do not have high enough coverage during the  
339 infectious period of SARS-CoV-2 to be effective at controlling community spread.

340 These are among the principal reasons why the U.S. has seen unmitigated increases in  
341 community transmission, hospitalizations, and deaths from COVID-19. Unless and until herd  
342 immunity can be achieved through a combination of natural infection and vaccine-induced



343 immunity, more nuanced understanding of the actual contribution of these factors over time is  
344 needed. This in turn will facilitate more effective government and community public health  
345 policies, actions and implementation strategies to control community spread, which is key to  
346 preventing avoidable hospitalizations and deaths, and ultimately maximizing the impact of  
347 vaccines. In areas where there is not an enforced lock down, our findings provide an evidence-  
348 base for federal, state, and local policy focus on risk factors that appear to be potential drivers of  
349 late-phase pandemic spread, such as indoor dining, mass gatherings, or not wearing masks when  
350 outside the home.

351 Data on more recent seroconversions occurring between May 2020 and January 2021 in our  
352 cohort suggest that elevated risk among essential workers, observed early in the U.S. pandemic,  
353 has persisted. Essential workers risk exposure to SARS-CoV-2 not only in their workplace(s),  
354 but also in their communities and as part of their commutes to and from work if they need to use  
355 public transportation. The increased burden of risk of SARS-CoV-2 infection in essential  
356 workers is then shared with their household members, among whom transmission is very  
357 efficient.<sup>19</sup> Along with this comes a higher burden of stress and anxiety among essential  
358 workers.<sup>20</sup> The most immediate action that governments can take to help keep essential workers  
359 safe is to minimize community transmission so that they are less likely to be exposed in the  
360 workplace or as part of their commutes. Policies and other strategies should be considered and  
361 implemented to ensure workplace safety (high quality masks, distancing, ventilation, paid sick  
362 leave for those that cannot afford to miss work) and the safety of public transportation. Any  
363 strategies should include prioritized access to SARS-CoV-2 vaccines for essential workers and,  
364 until or in the absence of vaccination, rapid testing for essential workers and members of their  
365 households. FDA-approved fully at-home rapid testing options are becoming more readily  
366 available with or without a prescription, and past research has indicated an overall increase in the  
367 uptake of testing with the addition of at-home testing options,<sup>21,22</sup> making them a potentially  
368 important strategy to increase early identification of new infections and subsequent interventions  
369 to prevent onward transmission. In this later phase of the pandemic, healthcare workers in our  
370 cohort had borderline elevated risk. Healthcare workers in the U.S. could be expected to have  
371 lower risk of SARS-CoV-2 exposure in the workplace due to focused efforts to mitigate risk via  
372 improved access to personal protective equipment and engineering controls. However, healthcare

373 workers also have ongoing community exposure, including possibly during their commutes to  
374 and from work, that could put them at higher risk of SARS-CoV-2 exposure and acquisition.

375 Our study provides epidemiologic evidence of increased risk for a number of key exposures.  
376 Living in more crowded households, defined as living in a multi-unit (i.e., apartment) building  
377 with 4 or more household members, was associated with a 60% higher incidence of SARS-CoV-  
378 2 infection compared with those living in less crowded households. Household transmission of  
379 SARS-CoV-2 occurs with very high attack rates, and may also increase the risk of more severe  
380 COVID-19 disease, requiring hospitalization.<sup>23</sup> Household crowding, more than population  
381 density, was shown to be a characteristic of community transmission ‘hotspots’ in a recent  
382 ecological analysis from the early phase of the pandemic.<sup>24</sup> When there are possible or confirmed  
383 cases of SARS-CoV-2 among household members, when background community transmission is  
384 substantial, or when the possibility of exposure outside the household is high (e.g., essential  
385 workers), our study and others<sup>25</sup> suggest mask use in the household should be considered,  
386 especially when it is otherwise not possible to limit potential exposure and spread in the  
387 household by isolating or sequestering away from others. As the vaccine rollout continues, this is  
388 particularly important to protect unvaccinated household members who may be at high risk for a  
389 severe COVID-19 outcome.

390 We characterized the potential contribution of several other key risk factors, some of which  
391 have been, or could be, the focus of state and federal policies, including dining indoors at a  
392 restaurant/bar, visiting a place of worship, inconsistent mask use while grocery shopping or  
393 visiting non-household members indoors (especially without masks), visiting a salon/gym,  
394 gathering indoors in groups of 10 or more, and recent travel by airplane during the pandemic.  
395 Working indoors, even while always masking but especially while never wearing a mask, was  
396 strongly associated with higher infection rates. In addition to being potential individual policy  
397 focus areas, we note that all of these risks can be mitigated by social distancing, workplace  
398 safety, increased mask use, use of more effective masks (e.g., KN95), and use of more than one  
399 mask.<sup>26-28</sup>

400 Finally, detailed examination of 303 individuals with serologic evidence of past SARS-CoV-  
401 2 infection showed major gaps in the reach of public health interventions aimed at testing, self-  
402 isolation, and contact tracing for people with SARS-CoV-2 (and their contacts). Indeed, many  
403 with evidence of prior SARS-CoV-2 infection did not report a prior positive PCR test, and a

404 substantial proportion were asymptomatic, both greatly hindering the ability of public health  
405 efforts to control spread. Furthermore, few people who had evidence of prior SARS-CoV-2  
406 infection in our study reported having been reached by contact tracers. When considering the  
407 large proportion of people with SARS-CoV-2 who have asymptomatic infection, undiagnosed  
408 infection (with or without symptoms), the low likelihood of diagnosis during the pre-  
409 symptomatic phase, the high number of new daily diagnoses and the often long delay between  
410 testing and return of results, contact tracing (a strategy that requires rapid response and action  
411 with high coverage early in the infectious period) is likely not a feasible strategy to control  
412 community spread in the U.S.. Limited public health resources may be better spent instead on  
413 messaging that emphasizes the importance of self-isolation after symptom onset or a positive  
414 test. Verbal, written and electronic (SMS text, email) messaging should occur at the time of the  
415 test, rather than after results are returned. In the event of a positive result, messaging at the time  
416 of testing should also include instructions to notify close contacts, including in workplaces, that  
417 they should quarantine and, if symptoms develop, self-isolate.

418 A shift in emphasis and resources away from contact tracing as a strategy to control  
419 community spread would provide much needed resources at the state and local level to facilitate  
420 more rapid and targeted delivery of vaccination, which has faltered in many areas to date. Many  
421 in our cohort, as across the U.S., are not yet vaccinated, not yet eligible for or are not currently  
422 willing to undergo vaccination<sup>29</sup>, and will remain at risk for months to come. Accelerating  
423 vaccine rollout, especially among those at high risk for a severe SARS-CoV-2 outcome and  
424 essential workers, has the potential to save tens of thousands of lives.

425 All of the potential risk factors described in our study and the low uptake of public health  
426 strategies conspire to create a perpetually disparate burden of risk among Hispanic and non-  
427 Hispanic Black persons and essential workers, as well as their household members and their  
428 communities. Our study suggests these inequalities have not been addressed to date in the U.S.,  
429 and the ultimate drivers, which relate to structural racism and possibly other factors, need to be  
430 unpacked by health departments and researchers.<sup>30</sup> There has been much research focused on  
431 comorbid medical conditions and other biologic factors that may increase the risk of SARS-  
432 CoV-2 acquisition or severity.<sup>31-33</sup> However, non-biological structural factors are the major  
433 drivers of COVID-19 infection and severe outcomes, and the inequities by race/ethnicity,  
434 occupation, geography, and income. These non-biological structural factors, such as household

435 crowding, the need to go to work to avoid income loss, and inequitable access to SARS-CoV-2  
436 testing<sup>34</sup>, create a disparate burden of SARS-CoV-2 exposure and incidence.<sup>35</sup> To date, no  
437 targeted strategies or policies have been deployed that aim to protect those who cannot afford  
438 missing work, including, but not only, essential workers. These disparities in SARS-CoV-2  
439 exposure, incidence, hospitalization and death will likely be perpetuated and likely exacerbated  
440 by differential uptake of the COVID-19 vaccines, driven by potentially flawed implementation  
441 strategies that prevent equitable access to vaccination. It is incumbent upon public health leaders,  
442 decision makers, and policy makers to anticipate and proactively design pandemic response  
443 implementation strategies, including metrics, that account for and counteract the fundamental  
444 and prevailing structural forces that without fail will otherwise create, perpetuate, or exacerbate  
445 inequities in safety, health and well-being.<sup>36-39</sup>

446 Strengths of our cohort study include its prospective design, allowing direct observation of  
447 seroconversions and incident COVID-19 infection among those who had no serologic evidence  
448 of prior SARS-CoV-2 infection, with and without risk factors. Our cohort is also geographically  
449 and sociodemographically diverse, facilitating assessment of geographic differences and  
450 racial/ethnic disparities. We also measured and were able to estimate incidence rates associated  
451 with a range of relevant epidemiologic risk factors.

452 Our study also has limitations worth noting. Most research studies deployed in the middle of  
453 a pandemic, including ours, may produce biased estimates since they may not include complete  
454 information on participants who died from COVID-19, or were too sick or otherwise too busy to  
455 participate in the research activities, or enrolled but became lost to follow-up. Moreover, it is  
456 possible that those who thought they had SARS-CoV-2 or were tested outside the study may  
457 have been more or less likely to participate in follow-up serologic testing, which would lead our  
458 seroincidence estimates to be biased in either direction. However, there was no systematic  
459 difference between those who tested in Period 1 and Period 2 (Table S1). Separately, while we  
460 have corrected our cumulative incidence estimates for laboratory test error<sup>18</sup>, the *observed*  
461 cumulative incidence in our cohort may be lower than the *true* cumulative incidence in our  
462 cohort because of waning of SARS-CoV-2 antibodies. Recent studies suggest waning of  
463 antibodies to both nucleocapsid and spike proteins<sup>2</sup>, which combined with the timing of  
464 specimen collection relative to infection for many participants in our cohort (median of 190  
465 days)<sup>9</sup>, could mean that we have underestimated the true cumulative incidence. Next, as with any

466 observational cohort study, estimated associations between SARS-CoV-2 risk factors and  
467 incidence are subject to confounding. The crude associations we presented could be over- or  
468 underestimated, and also may vary by setting. For example, the effect of indoor dining may be  
469 different in areas of lower versus higher levels of community transmission. Our study also had  
470 limited statistical power due to our sample size and the relatively short duration of follow-up.  
471 Finally, while our study is well-suited to characterize the risks related to SARS-CoV-2  
472 acquisition, it is less well-suited to examine factors related to onward transmission from  
473 participants who had SARS-CoV-2 infection. However, in lieu of this, we have endeavored to  
474 describe the coverage of public health-related outreach to persons in our cohort who had  
475 evidence of past SARS-CoV-2 infection and identified some areas in need of improvement, such  
476 as the need for improvements in the uptake of testing and self-isolation.

477

## 478 **Conclusion**

479 Modifiable risk factors and poor reach of public health strategies continue to drive transmission  
480 of SARS-CoV-2 across the U.S.. It is critical to address inequities in incidence, reduce risk  
481 factors, and improve the reach of public health strategies of testing and self-isolation in the  
482 vaccine era. Given the properties of the SARS-CoV-2 virus, including the substantial  
483 asymptomatic and pre-symptomatic phases during the SARS-CoV-2 infectious period, the  
484 magnitude of cases and the need to act quickly, contact tracing is not a viable public health  
485 strategy to control the spread of the pandemic in the U.S.. Our cumulative incidence estimates  
486 suggest that many in our cohort remain at risk for SARS-CoV-2, including those with risk factors  
487 for infection and severe disease. While SARS-CoV-2 vaccines will likely reduce the risk of  
488 COVID-19 disease and possibly SARS-CoV-2 acquisition substantially for this group, this will  
489 likely take some time due to both the pace of the vaccine rollout and vaccine hesitancy. The  
490 CHASING COVID Cohort Study will continue to monitor SARS-CoV-2 outcomes, including  
491 vaccine uptake, through December 2021.

492

493

## 494 **CONTRIBUTORS**

495 DN, MR, SGK, MMR, conceptualized the study. MR, MC and DN performed statistical  
496 analyses. DN and MR wrote the first draft of the paper. DN, MR, MC, SGK, and AP contributed

497 to interpreting the data, DN, RZ, MR, MC, SGK, WY, AB, CM, SK, AM, MMR, DW, AP, LW,  
498 CG and to the writing and revising of the manuscript, SGK, WY, AB, CM, SK, and DN  
499 contributed to data collection, cleaning and management. DN, SGK, MMR and CG contributed  
500 to obtaining funding for the research.

501

## 502 **ACKNOWLEDGEMENTS**

503 The authors wish to thank the participants of the CHASING COVID Cohort Study. We are  
504 grateful to you for your contributions to the advancement of science around the SARS-CoV-2  
505 pandemic. We thank Prof. Patrick Sullivan and MTL for local validation work on the serologic  
506 assays for use with DBS that greatly benefited our study. We are also grateful to MTL Labs for  
507 processing specimen collection kits and serologic testing of our cohort's specimens.

508

## 509 **FUNDING**

510 Funding for this project is provided by The National Institute of Allergy and Infectious Diseases  
511 (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the  
512 CUNY Institute for Implementation Science in Population Health ([cunyisph.org](http://cunyisph.org)) and the  
513 COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy,  
514 and National Institute of Child Health and Human Development grant P2C HD050924 (Carolina  
515 Population Center).

516 **REFERENCES**

- 517 1. CDC, COVID Data Tracker (2020), (available at <https://covid.cdc.gov/covid-data-tracker/>).
- 518 2. K. L. Bajema, R. E. Wiegand, K. Cuffe, S. V. Patel, R. Iachan, T. Lim, A. Lee, D. Moyse, F.  
519 P. Havers, L. Harding, A. M. Fry, A. J. Hall, K. Martin, M. Biel, Y. Deng, W. A. Meyer 3rd,  
520 M. Mathur, T. Kyle, A. V. Gundlapalli, N. J. Thornburg, L. R. Petersen, C. Edens,  
521 Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern.*  
522 *Med.* (2020), doi:10.1001/jamainternmed.2020.7976.
- 523 3. F. J. Angulo, L. Finelli, D. L. Swerdlow, Estimation of US SARS-CoV-2 Infections,  
524 Symptomatic Infections, Hospitalizations, and Deaths Using Seroprevalence Surveys. *JAMA*  
525 *Netw Open.* **4**, e2033706 (2021).
- 526 4. H. Kalish, C. Klumpp-Thomas, S. Hunsberger, H. A. Baus, M. P. Fay, N. Siripong, J. Wang,  
527 J. Hicks, J. Mehalko, J. Travers, M. Drew, K. Pauly, J. Spathies, T. Ngo, K. M. Adusei, M.  
528 Karkanitsa, J. A. Croker, Y. Li, B. I. Graubard, L. Czajkowski, O. Belliveau, C. Chairez, K.  
529 Snead, P. Frank, A. Shunmugavel, A. Han, L. T. Giurgea, L. A. Rosas, R. Bean, R. Athota,  
530 A. Cervantes-Medina, M. Gouzoulis, B. Heffelfinger, S. Valenti, R. Caldararo, M. M.  
531 Kolberg, A. Kelly, R. Simon, S. Shafiq, V. Wall, S. Reed, E. W. Ford, R. Lokwani, J.-P.  
532 Denson, S. Messing, S. G. Michael, W. Gillette, R. P. Kimberly, S. E. Reis, M. D. Hall, D.  
533 Esposito, M. J. Memoli, K. Sadtler, Mapping a Pandemic: SARS-CoV-2 Seropositivity in  
534 the United States. *medRxiv* (2021), doi:10.1101/2021.01.27.21250570.
- 535 5. D. Buitrago-Garcia, D. Egli-Gany, M. J. Counotte, S. Hossmann, H. Imeri, A. M. Ipekci, G.  
536 Salanti, N. Low, Occurrence and transmission potential of asymptomatic and  
537 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.  
538 *PLoS Med.* **17**, e1003346 (2020).
- 539 6. H. J. Hutchins, B. Wolff, R. Leeb, J. Y. Ko, E. Odom, J. Willey, A. Friedman, R. H. Bitsko,  
540 COVID-19 Mitigation Behaviors by Age Group - United States, April-June 2020. *MMWR*  
541 *Morb. Mortal. Wkly. Rep.* **69**, 1584–1590 (2020).
- 542 7. M. Lipsitch, D. L. Swerdlow, L. Finelli, Defining the epidemiology of Covid-19—studies



- 543 needed. *N. Engl. J. Med.* **382**, 1194–1196 (2020).
- 544 8. D. P. Oran, E. J. Topol, The Proportion of SARS-CoV-2 Infections That Are Asymptomatic  
545 : A Systematic Review. *Ann. Intern. Med.* (2021), doi:10.7326/M20-6976.
- 546 9. M. Robertson, S. Kulkarni, A. Berry, C. Mirzayi, A. R. Maroko, R. Zimba, D.  
547 Westmoreland, C. Grov, A. Parcesepe, L. Waldron, D. Nash, A national prospective cohort  
548 study of SARS/COV2 pandemic outcomes in the U.S.: The CHASING COVID Cohort.  
549 *medRxiv* (2020), doi:10.1101/2020.04.28.20080630.
- 550 10. C. Grov, D. A. Westmoreland, P. B. Carneiro, M. Stief, C. MacCrate, C. Mirzayi, D. W.  
551 Pantalone, V. V. Patel, D. Nash, Recruiting vulnerable populations to participate in HIV  
552 prevention research: findings from the Together 5000 cohort study. *Annals of Epidemiology.*  
553 **35** (2019), pp. 4–11.
- 554 11. D. Nash, M. Stief, C. MacCrate, C. Mirzayi, V. V. Patel, D. Hoover, D. W. Pantalone, S.  
555 Golub, G. Millett, A. B. D’Angelo, D. A. Westmoreland, C. Grov, A Web-Based Study of  
556 HIV Prevention in the Era of Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative  
557 Gay and Bisexual Men, Transmen, and Transwomen Who Have Sex With Men: Protocol for  
558 an Observational Cohort Study. *JMIR Research Protocols.* **8** (2019), p. e13715.
- 559 12. C. Grov, D. Westmoreland, H. J. Rendina, D. Nash, Seeing Is Believing? Unique  
560 Capabilities of Internet-Only Studies as a Tool for Implementation Research on HIV  
561 Prevention for Men Who Have Sex With Men: A Review of Studies and Methodological  
562 Considerations. *J. Acquir. Immune Defic. Syndr.* **82 Suppl 3**, S253–S260 (2019).
- 563 13. CDC - BRFSS (2020), (available at <https://www.cdc.gov/brfss/index.html>).
- 564 14. T. A. Santibanez, J. A. Singleton, S. S. Santibanez, P. Wortley, B. P. Bell, Socio-  
565 demographic differences in opinions about 2009 pandemic influenza A (H1N1) and seasonal  
566 influenza vaccination and disease among adults during the 2009--2010 influenza season.  
567 *Influenza Other Respi. Viruses.* **7**, 383–392 (2013).
- 568 15. S. Kumar, S. C. Quinn, K. H. Kim, L. H. Daniel, V. S. Freimuth, The impact of workplace  
569 policies and other social factors on self-reported influenza-like illness incidence during the


- 570 2009 H1N1 pandemic. *Am. J. Public Health.* **102**, 134–140 (2012).
- 571 16. M. T. Niles, R. Neff, E. Biehl, F. Bertmann, E. H. Morgan, T. Wentworth, Food Access and  
572 Security During Coronavirus Survey- Version 1.0 (2020), , doi:10.7910/DVN/RQ6NMG.
- 573 17. Center for Devices, Radiological Health, EUA Authorized Serology Test Performance  
574 (2021), (available at [https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance)  
575 [performance](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance)).  
576
- 577 18. C. T. Sempos, L. Tian, Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit  
578 Error. *Am. J. Epidemiol.* **190**, 109–115 (2021).
- 579 19. Z. J. Madewell, Y. Yang, I. M. Longini Jr, M. E. Halloran, N. E. Dean, Household  
580 Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis. *JAMA Netw Open.*  
581 **3**, e2031756 (2020).
- 582 20. A. M. Parcesepe, M. Robertson, A. Berry, A. Maroko, R. Zimba, C. Grov, D.  
583 Westmoreland, S. Kulkarni, M. Rane, W. Salgado-You, C. Mirzayi, L. Waldron, D. Nash,  
584 The relationship between anxiety, health, and potential stressors among adults in the United  
585 States during the COVID-19 pandemic. *medRxiv* (2020), doi:10.1101/2020.10.30.20221440.
- 586 21. R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A. Parcesepe, L.  
587 Waldron, M. Rane, S. Kochhar, M. Robertson, A. Maroko, C. Grov, D. Nash, SARS-CoV-2  
588 Testing Service Preferences of Adults in the United States: Discrete Choice Experiment.  
589 *JMIR Public Health Surveill.* **6**, e25546 (2020).
- 590 22. M. L. Romo, R. Zimba, S. Kulkarni, A. Berry, W. You, C. Mirzayi, D. Westmoreland, A.  
591 M. Parcesepe, L. Waldron, M. Rane, S. Kochhar, M. Robertson, A. R. Maroko, C. Grov, D.  
592 Nash, Patterns of SARS-CoV-2 testing preferences in a national cohort in the United States.  
593 *medRxiv* (2020), doi:10.1101/2020.12.22.20248747.
- 594 23. D. Nash, S. Qasmieh, M. Robertson, M. Rane, R. Zimba, S. Kulkarni, A. Berry, W. You, C.  
595 Mirzayi, D. Westmoreland, A. Parcesepe, L. Waldron, S. Kochhar, A. R. Maroko, C. Grov,  
596 Household factors and the risk of severe COVID-like illness early in the US pandemic.

- 597 *medRxiv* (2020), doi:10.1101/2020.12.03.20243683.
- 598 24. A. Maroko, D. Nash, B. Pavlonis, Covid-19 and Inequity: A comparative spatial analysis of  
599 New York City and Chicago hot spots. *J. Urban Health* (2020).
- 600 25. Y. Wang, H. Tian, L. Zhang, M. Zhang, D. Guo, W. Wu, X. Zhang, G. L. Kan, L. Jia, D.  
601 Huo, B. Liu, X. Wang, Y. Sun, Q. Wang, P. Yang, C. R. MacIntyre, Reduction of secondary  
602 transmission of SARS-CoV-2 in households by face mask use, disinfection and social  
603 distancing: a cohort study in Beijing, China. *BMJ Glob Health*. **5** (2020),  
604 doi:10.1136/bmjgh-2020-002794.
- 605 26. CDC, Scientific brief: Community use of cloth masks to control the spread of SARS-CoV-2  
606 (2020), (available at <https://www.cdc.gov/coronavirus/2019-ncov/more/masking-science-sars-cov2.html>).
- 608 27. Y. Li, M. Liang, L. Gao, M. Ayaz Ahmed, J. P. Uy, C. Cheng, Q. Zhou, C. Sun, Face masks  
609 to prevent transmission of COVID-19: A systematic review and meta-analysis. *Am. J. Infect.*  
610 *Control* (2020), doi:10.1016/j.ajic.2020.12.007.
- 611 28. D. K. Chu, E. A. Akl, S. Duda, K. Solo, S. Yaacoub, H. J. Schünemann, COVID-19  
612 Systematic Urgent Review Group Effort (SURGE) study authors, Physical distancing, face  
613 masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and  
614 COVID-19: a systematic review and meta-analysis. *Lancet*. **395**, 1973–1987 (2020).
- 615 29. K. A. Fisher, S. J. Bloomstone, J. Walder, S. Crawford, H. Fouayzi, K. M. Mazor, Attitudes  
616 Toward a Potential SARS-CoV-2 Vaccine : A Survey of U.S. Adults. *Ann. Intern. Med.* **173**,  
617 964–973 (2020).
- 618 30. L. N. Borrell, J. R. Elhawary, E. Fuentes-Afflick, J. Witonsky, N. Bhakta, A. H. B. Wu, K.  
619 Bibbins-Domingo, J. R. Rodríguez-Santana, M. A. Lenoir, J. R. Gavin 3rd, R. A. Kittles, N.  
620 A. Zaitlen, D. S. Wilkes, N. R. Powe, E. Ziv, E. G. Burchard, Race and Genetic Ancestry in  
621 Medicine - A Time for Reckoning with Racism. *N. Engl. J. Med.* **384**, 474–480 (2021).
- 622 31. A. Emami, F. Javanmardi, N. Pirbonyeh, A. Akbari, Prevalence of underlying diseases in  
623 hospitalized patients with COVID-19: a systematic review and meta-analysis. *Archives of*

- 624 *academic emergency medicine*. **8** (2020) (available at  
625 <https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7096724/>).
- 626 32. S. Richardson, J. S. Hirsch, M. Narasimhan, J. M. Crawford, T. McGinn, K. W. Davidson,  
627 the Northwell COVID-19 Research Consortium, D. P. Barnaby, L. B. Becker, J. D. Chelico,  
628 S. L. Cohen, J. Cookingham, K. Coppa, M. A. Diefenbach, A. J. Dominello, J. Duer-Hefelee,  
629 L. Falzon, J. Gitlin, N. Hajjzadeh, T. G. Harvin, D. A. Hirschwerk, E. J. Kim, Z. M. Kozel,  
630 L. M. Marrast, J. N. Mogavero, G. A. Osorio, M. Qiu, T. P. Zanos, Presenting  
631 Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With  
632 COVID-19 in the New York City Area. *JAMA*. **323**, 2052–2059 (2020).
- 633 33. C. M. Petrilli, S. A. Jones, J. Yang, H. Rajagopalan, L. O’Donnell, Y. Chernyak, K. A.  
634 Tobin, R. J. Cerfolio, F. Francois, L. I. Horwitz, Factors associated with hospital admission  
635 and critical illness among 5279 people with coronavirus disease 2019 in New York City:  
636 prospective cohort study. *BMJ*. **369**, m1966 (2020).
- 637 34. A. Mody, K. Pfeifauf, E. H. Geng, Using Lorenz Curves to Measure Racial Inequities in  
638 COVID-19 Testing. *JAMA Netw Open*. **4**, e2032696 (2021).
- 639 35. G. Ogedegbe, J. Ravenell, S. Adhikari, M. Butler, T. Cook, F. Francois, E. Iturrate, G. Jean-  
640 Louis, S. A. Jones, D. Onakomaiya, C. M. Petrilli, C. Pulgarin, S. Regan, H. Reynolds, A.  
641 Seixas, F. M. Volpicelli, L. I. Horwitz, Assessment of Racial/Ethnic Disparities in  
642 Hospitalization and Mortality in Patients With COVID-19 in New York City. *JAMA Netw*  
643 *Open*. **3**, e2026881 (2020).
- 644 36. D. Nash, E. Geng, Goal-Aligned, Epidemic Intelligence for the Public Health Response to  
645 the COVID-19 Pandemic. *Am. J. Public Health*. **110**, 1154–1156 (2020).
- 646 37. D. Nash, Designing and Disseminating Metrics to Support Jurisdictional Efforts to End the  
647 Public Health Threat Posed by HIV Epidemics. *Am. J. Public Health*. **110**, 53–57 (2020).
- 648 38. Z. D. Bailey, J. M. Feldman, M. T. Bassett, How Structural Racism Works - Racist Policies  
649 as a Root Cause of U.S. Racial Health Inequities. *N. Engl. J. Med.* (2020),  
650 doi:10.1056/NEJMms2025396.


- 651 39. Z. D. Bailey, N. Krieger, M. Agénor, J. Graves, N. Linos, M. T. Bassett, Structural racism  
652 and health inequities in the USA: evidence and interventions. *Lancet*. **389**, 1453–1463  
653 (2017).

## SUPPLEMENTAL MATERIALS



**Fig. S1.**

Geographic distribution of CHASING COVID Cohort participants, N=6,745



**Fig. S2.**

Timing of first (red) and second (blue) dried blood spot specimen collection in the CHASING COVID Cohort Study, including follow-up interview milestones



Table S1. Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

|                        | All participants |       | Participants with one or more serologic test |      | Participants with a serologic test in Period 1 (May-September 2020) |      | Participants with a serologic test in Period 2 (November 2020-January 2021)* |      |
|------------------------|------------------|-------|--|------|---|------|--|------|
|                        | N                | %     | N  | %    | N   | %    | N  | %    |
| <b>Total</b>           | 6,745            | 100%  | 4459   | 66%  | 4235  | 63%  | 3615   | 54%  |
| <b>Age*</b>            |                  |       |  |      |   |      |  |      |
| Median (IQR)           | 37 (29,51)       |       | 41 (31, 55)                                  |      | 41, (32, 56)  |      | 41, (32, 56)   |      |
| 18-29                  | 1804             | 26.75 | 861  | 19.3 | 801   | 18.9 | 656  | 18.4 |
| 30-39                  | 1965             | 29.13 | 1246   | 27.9 | 1177  | 27.8 | 1004   | 27.8 |
| 40-49                  | 1160             | 17.2  | 846  | 19.0 | 809   | 19.1 | 686  | 19.0 |
| 50-59                  | 792              | 11.74 | 646  | 14.5 | 620   | 14.6 | 541  | 15.0 |
| 60+                    | 1024             | 15.18 | 860  | 19.3 | 828   | 19.6 | 719  | 19.9 |
| <b>Gender</b>          |                  |       |  |      |   |      |  |      |
| Male                   | 3047             | 45.17 | 1991   | 44.7 | 1900  | 44.9 | 1607   | 44.5 |
| Female                 | 3527             | 52.29 | 2337   | 52.4 | 2212  | 52.2 | 1906   | 52.7 |
| Non-Binary/Transgender | 171              | 2.54  | 131  | 2.9  | 123   | 2.9  | 102  | 2.8  |
| <b>Race/Ethnicity*</b> |                  |       |  |      |   |      |  |      |
| Non-Hispanic White     | 3859             | 56.8  | 2953   | 66.3 | 2833  | 66.9 | 2410   | 66.7 |
| Hispanic               | 1310             | 19.42 | 669  | 15.0 | 623   | 14.7 | 550  | 15.2 |
| Non-Hispanic Black     | 851              | 12.62 | 369  | 8.3  | 342   | 8.1  | 285  | 7.9  |
| Asian                  | 439              | 6.51  | 283  | 6.3  | 262   | 6.2  | 228  | 6.3  |
| Pacific Islander       | 36               | 0.53  | 18   | 0.4  | 18  | 0.4  | 15   | 0.4  |
| Other                  | 250              | 3.71  | 167  | 3.8  | 157   | 3.7  | 127  | 3.5  |
| <b>Education</b>       |                  |       |  |      |   |      |  |      |
| Less than high school  | 123              | 1.82  | 52   | 1.2  | 47  | 1.1  | 43   | 1.2  |
| High school graduate   | 879              | 13.03 | 399  | 9.0  | 367   | 8.7  | 308  | 8.5  |
| Some college           | 1889             | 28.01 | 1126   | 25.3 | 1053  | 24.9 | 871  | 24.1 |

|                                       |      |       |      |      |      |      |      |      |
|---------------------------------------|------|-------|------|------|------|------|------|------|
| College graduate                      | 3854 | 57.14 | 2882 | 64.6 | 2768 | 65.4 | 2393 | 66.2 |
| <b>Employment*</b>                    |      |       |      |      |      |      |      |      |
| Employed                              | 4249 | 62.99 | 2741 | 61.5 | 2613 | 61.7 | 2216 | 61.3 |
| Out of work                           | 830  | 12.31 | 535  | 12.0 | 503  | 11.9 | 429  | 11.9 |
| Homemaker                             | 352  | 5.22  | 240  | 5.4  | 225  | 5.3  | 194  | 5.4  |
| Student                               | 610  | 9.04  | 362  | 8.1  | 330  | 7.8  | 283  | 7.8  |
| Retired                               | 704  | 10.44 | 581  | 13.0 | 564  | 13.3 | 493  | 13.6 |
| <b>Household income*</b>              |      |       |      |      |      |      |      |      |
| Less than \$35,000                    | 2180 | 32.32 | 1288 | 28.9 | 1213 | 28.6 | 1009 | 27.9 |
| \$35-49,999                           | 753  | 11.16 | 487  | 10.9 | 457  | 10.8 | 402  | 11.1 |
| \$50-69,999                           | 960  | 14.23 | 635  | 14.2 | 600  | 14.2 | 532  | 14.7 |
| \$70-99,999                           | 1058 | 15.69 | 734  | 16.5 | 706  | 16.7 | 624  | 17.3 |
| \$100,000+                            | 1794 | 26.6  | 1315 | 29.5 | 1259 | 29.7 | 1048 | 29.0 |
| <b>Setting*</b>                       |      |       |      |      |      |      |      |      |
| Urban                                 | 2974 | 44.09 | 1962 | 44.0 | 1873 | 44.2 | 1572 | 43.5 |
| Suburban                              | 1760 | 26.09 | 1143 | 25.6 | 1092 | 25.8 | 928  | 25.7 |
| Rural                                 | 2011 | 29.81 | 1354 | 30.4 | 1270 | 30.0 | 1115 | 30.8 |
| <b>Geographic region*</b>             |      |       |      |      |      |      |      |      |
| Northeast                             | 1882 | 27.9  | 1294 | 29.0 | 1244 | 29.4 | 1023 | 28.3 |
| Midwest                               | 1127 | 16.71 | 794  | 17.8 | 760  | 18.0 | 655  | 18.1 |
| South                                 | 2103 | 31.18 | 1269 | 28.5 | 1188 | 28.1 | 1037 | 28.7 |
| West                                  | 1625 | 24.09 | 1097 | 24.6 | 1038 | 24.5 | 896  | 24.8 |
| US Dependent Territories              | 8    | 0.12  | 5    | 0.1  | 5    | 0.1  | 4    | 0.1  |
| <b>Healthcare worker*</b>             |      |       |      |      |      |      |      |      |
| No                                    | 5948 | 88.18 | 4042 | 90.7 | 3835 | 90.6 | 3283 | 90.8 |
| Yes                                   | 797  | 11.82 | 417  | 9.4  | 400  | 9.5  | 332  | 9.2  |
| <b>Essential worker</b>               |      |       |      |      |      |      |      |      |
| No                                    | 5601 | 83    | 3858 | 86.5 | 3662 | 86.5 | 3137 | 86.8 |
| Yes                                   | 1144 | 17    | 601  | 13.5 | 573  | 13.5 | 478  | 13.2 |
| <b>Higher risk for severe COVID**</b> |      |       |      |      |      |      |      |      |
| No                                    | 3167 | 46.95 | 2074 | 46.5 | 1974 | 46.6 | 1669 | 46.2 |
| Yes                                   | 3578 | 53.05 | 2385 | 53.5 | 2261 | 53.4 | 1946 | 53.8 |

\*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common

---

value for this variable

\*\* >60 years old, or reported co-morbidity, or current smoker.

**Table S1.**

Baseline characteristics and serologic testing of CHASING COVID Cohort Study participants by time period of testing

Table S2. Crude and adjusted\*\* cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time period of testing

|                        | All unique participants with a serologic test result<br>(Period 1 or Period 2) N=4,459 |             |                                     |  | Participants with a serologic test in Period 1<br>(N=4,235) |             |                                     |  | Participants with a serologic test in Period 2<br>(N=3,615) |             |                                     |  |
|------------------------|--|-------------|-------------------------------------|--|---|-------------|-------------------------------------|--|---|-------------|-------------------------------------|--|
|                        | Number positive  | Total       | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) | Number positive   | Total       | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) | Number positive   | Total       | Crude cumulative incidence (95% CI) | Adjusted cumulative incidence (95% CI) |
| <b>Total</b>           | <b>303</b>   | <b>4459</b> | <b>6.8 (6.1, 7.6)</b>               | <b>6.3 (5.5, 7.1)</b>                  | <b>134</b>  | <b>4235</b> | <b>3.2 (2.6, 3.7)</b>               | <b>2.6 (2, 3.1)</b>                    | <b>258</b>  | <b>3615</b> | <b>7.2 (6.3, 8)</b>                 | <b>6.7 (5.8, 7.5)</b>                  |
| <b>Age group*</b>      |  |             |                                     |  |   |             |                                     |  |   |             |                                     |  |
| 18-29                  | 66   | 861         | 7.7 (5.9, 9.4)                      | 7.2 (5.3, 8.9)                         | 28  | 801         | 3.5 (2.2, 4.8)                      | 2.4 (1.1, 3.7)                         | 57  | 665         | 8.6 (6.4, 10.7)                     | 7.6 (5.4, 9.7)                         |
| 30-39                  | 94   | 1246        | 7.5 (6.1, 9.0)                      | 7 (5.5, 8.5)                           | 46  | 1177        | 3.9 (2.8, 5.0)                      | 2.8 (1.7, 4)                           | 76  | 1004        | 7.6 (5.9, 9.2)                      | 6.6 (4.9, 8.2)                         |
| 40-49                  | 60   | 846         | 7.1 (5.4, 8.8)                      | 6.6 (4.8, 8.3)                         | 27  | 809         | 3.3 (2.1, 4.6)                      | 2.2 (1, 3.5)                           | 47  | 686         | 6.9 (5, 8.7)                        | 5.9 (3.9, 7.7)                         |
| 50-59                  | 45   | 646         | 7.1 (5.1, 9.1)                      | 6.6 (4.5, 8.6)                         | 20  | 620         | 3.4 (2, 4.8)                        | 2.3 (0.9, 3.7)                         | 44  | 541         | 8.3 (6, 10.6)                       | 7.3 (5, 9.6)                           |
| 60+                    | 38   | 860         | 4.4 (3.1, 5.8)                      | 3.8 (2.5, 5.2)                         | 13  | 828         | 1.6 (0.7, 2.4)                      | 0.5 (0, 1.3)                           | 34  | 719         | 4.7 (3.2, 6.3)                      | 3.6 (2.1, 5.3)                         |
| <b>Gender</b>          |  |             |                                     |  |   |             |                                     |  |   |             |                                     |  |
| Male                   | 165  | 1991        | 8.3 (7.1, 9.5)                      | 7.8 (6.6, 9)                           | 79  | 1900        | 4.2 (3.3, 5.1)                      | 3.1 (2.2, 4)                           | 134   | 1607        | 8.3 (7, 9.7)                        | 7.3 (6, 8.7)                           |
| Female                 | 134  | 2337        | 5.8 (4.8, 6.7)                      | 5.2 (4.2, 6.2)                         | 54  | 2212        | 2.5 (1.8, 3.1)                      | 1.4 (0.7, 2)                           | 120   | 1906        | 6.4 (5.3, 7.4)                      | 5.4 (4.2, 6.4)                         |
| Non-Binary/Transgender | 4  | 131         | 3.1 (1.1, 6.1)                      | 2.5 (0.4, 5.5)                         | 1   | 123         | 0.8 (0, 2.4)                        | 0 (0, 1.3)                             | 4   | 102         | 3.9 (1.5, 7.7)                      | 2.8 (0, 6.7)                           |
| <b>Race/Ethnicity*</b> |  |             |                                     |  |   |             |                                     |  |   |             |                                     |  |
| Non-Hispanic White     | 174  | 2953        | 5.9 (5.1, 6.8)                      | 5.3 (4.5, 6.3)                         | 81  | 2833        | 2.9 (2.3, 3.5)                      | 1.8 (1.2, 2.4)                         | 156   | 2410        | 6.5 (5.5, 7.5)                      | 5.5 (4.4, 6.5)                         |
| Hispanic               | 71   | 669         | 10.6 (8.3, 13.0)                    | 10.2 (7.8, 12.6)                       | 26  | 623         | 4.2 (2.6, 5.8)                      | 3.1 (1.5, 4.8)                         | 57  | 550         | 10.4 (7.8, 12.9)                    | 9.4 (6.8, 11.9)                        |
| Non-Hispanic Black     | 31   | 369         | 8.4 (5.6, 11.2)                     | 7.9 (5, 10.8)                          | 13  | 342         | 3.8 (1.8, 5.8)                      | 2.7 (0.7, 4.8)                         | 25  | 285         | 8.8 (5.5, 12.1)                     | 7.8 (4.4, 11.1)                        |
| Asian                  | 16   | 283         | 5.7 (3.0, 8.3)                      | 5.1 (2.4, 7.8)                         | 9   | 262         | 3.4 (1.2, 5.6)                      | 2.3 (0.1, 4.6)                         | 12  | 228         | 5.3 (2.4, 8.2)                      | 4.2 (1.3, 7.2)                         |
| Pacific Islander       | 0  | 18          | 0 (0, 0)                            |  | 0   | 18          | 0 (0, 17.6)                         | 0 (0, 16.7)                            | 0   | 15          |                                     |  |
| Other                  | 11   | 167         | 6.6 (3.7, 11.4)                     | 6.1 (3.1, 11)                          | 5   | 157         | 3.2 (0.4, 5.9)                      | 2.1 (0, 4.9)                           | 8   | 127         | 6.3 (2.1, 10.5)                     | 5.3 (1, 9.5)                           |
| <b>Education</b>       |  |             |                                     |  |   |             |                                     |  |   |             |                                     |  |
| Less than high school  | 5  | 52          | 9.6 (1.6, 21.0)                     | 9.1 (0.9, 20.9)                        | 3   | 47          | 6.4 (0, 13.4)                       | 5.4 (0, 12.4)                          | 3   | 43          | 7 (0, 14.6)                         | 6 (0, 13.7)                            |
| High school graduate   | 34   | 399         | 8.5 (5.8, 11.3)                     | 8 (5.2, 10.9)                          | 13  | 367         | 3.5 (1.7, 5.4)                      | 2.4 (0.6, 4.3)                         | 29  | 308         | 9.4 (6.2, 12.7)                     | 8.4 (5.2, 11.7)                        |
| Some college           | 72   | 1126        | 6.4 (5.0, 7.8)                      | 5.9 (4.4, 7.3)                         | 29  | 1053        | 2.8 (1.8, 3.8)                      | 1.7 (0.7, 2.7)                         | 62  | 871         | 7.1 (5.4, 8.8)                      | 6.1 (4.3, 7.8)                         |
| College graduate       | 192  | 2882        | 6.7 (5.8, 7.6)                      | 6.2 (5.2, 7.1)                         | 89  | 2768        | 3.3 (2.6, 3.9)                      | 2.2 (1.5, 2.8)                         | 164   | 2393        | 6.9 (5.8, 7.9)                      | 5.9 (4.8, 6.9)                         |
| <b>Employment*</b>     |  |             |                                     |  |   |             |                                     |  |   |             |                                     |  |
| Employed               | 208  | 2741        | 7.6 (6.6, 8.6)                      | 7.1 (6.1, 8.1)                         | 95  | 2613        | 2.4 (1.5, 3.4)                      | 1.3 (0.4, 2.3)                         | 179   | 2216        | 8.1 (6.9, 9.2)                      | 7.1 (5.9, 8.2)                         |
| Out of work            | 34   | 535         | 6.4 (4.3, 8.4)                      | 5.9 (3.7, 7.9)                         | 15  | 503         | 1.9 (0.1, 3.7)                      | 0.8 (0, 2.6)                           | 26  | 429         | 6.1 (3.8, 8.3)                      | 5.1 (2.7, 7.3)                         |

|                           |     |      |                 |                 |     |      |                |                |     |      |                 |                 |
|---------------------------|-----|------|-----------------|-----------------|-----|------|----------------|----------------|-----|------|-----------------|-----------------|
| Homemaker                 | 14  | 240  | 6.2 (3.2, 9.3)  | 5.7 (2.6, 8.8)  | 6   | 225  | 3.5 (0.5, 6.4) | 2.4 (0, 5.4)   | 11  | 194  | 6.2 (3, 9.5)    | 5.2 (1.9, 8.5)  |
| Student                   | 24  | 362  | 6.7 (4.1, 9.2)  | 6.2 (3.5, 8.7)  | 10  | 330  | 2 (0, 4.7)     | 0.9 (0, 3.6)   | 21  | 283  | 7.4 (4.4, 10.5) | 6.4 (3.3, 9.5)  |
| Retired                   | 23  | 581  | 4.0 (2.4, 5.5)  | 3.4 (1.7, 4.9)  | 8   | 564  | 1.2 (0, 2.6)   | 0.1 (0, 1.5)   | 21  | 493  | 4.3 (2.5, 6)    | 3.2 (1.4, 5)    |
| <b>Household income*</b>  |     |      |                 |                 |     |      |                |                |     |      |                 |                 |
| Less than \$35,000        | 82  | 1288 | 6.4 (5.1, 7.8)  | 5.9 (4.5, 7.3)  | 31  | 1213 | 2.3 (1.4, 3.1) | 1.2 (0.3, 2)   | 71  | 1009 | 7.1 (5.5, 8.7)  | 6.1 (4.4, 7.7)  |
| \$35-49,999               | 40  | 487  | 8.2 (5.8, 10.6) | 7.7 (5.2, 10.2) | 17  | 457  | 3.7 (2, 5.4)   | 2.6 (0.9, 4.3) | 34  | 402  | 8.5 (5.7, 11.2) | 7.5 (4.7, 10.2) |
| \$50-69,999               | 39  | 635  | 6.1 (4.3, 8.0)  | 5.5 (3.7, 7.5)  | 16  | 600  | 2.7 (1.4, 4)   | 1.6 (0.3, 2.9) | 31  | 532  | 5.8 (3.8, 7.8)  | 4.8 (2.7, 6.8)  |
| \$70-99,999               | 57  | 734  | 7.8 (5.8, 9.7)  | 7.3 (5.2, 9.2)  | 26  | 706  | 3.7 (2.3, 5.1) | 2.6 (1.2, 4)   | 49  | 624  | 7.9 (5.7, 9.9)  | 6.9 (4.7, 8.9)  |
| \$100,000+                | 85  | 1315 | 6.5 (5.1, 7.8)  | 6 (4.5, 7.3)    | 44  | 1259 | 3.5 (2.5, 4.5) | 2.4 (1.4, 3.4) | 73  | 1048 | 6 (5.4, 8.5)    | 5 (4.3, 7.5)    |
| <b>Setting*</b>           |     |      |                 |                 |     |      |                |                |     |      |                 |                 |
| Urban                     | 136 | 1962 | 6.9 (5.8, 8.1)  | 6.4 (5.2, 7.6)  | 71  | 1873 | 3.9 (3, 4.8)   | 2.8 (1.9, 3.7) | 111 | 1572 | 7.1 (5.8, 8.3)  | 6.1 (4.8, 7.3)  |
| Suburban                  | 78  | 1143 | 6.8 (5.4, 8.3)  | 5.8 (4.3, 7.3)  | 35  | 1092 | 3.2 (2.2, 4.3) | 2.1 (1.1, 3.2) | 68  | 928  | 7.3 (5.7, 9)    | 6.3 (4.7, 8)    |
| Rural                     | 89  | 1354 | 6.7 (5.3, 8.0)  | 5.7 (4.2, 7)    | 28  | 1270 | 2.3 (1.5, 3.1) | 1.2 (0.4, 2)   | 79  | 1115 | 7.2 (5.7, 8.7)  | 6.2 (4.7, 7.7)  |
| <b>Geographic region*</b> |     |      |                 |                 |     |      |                |                |     |      |                 |                 |
| Northeast                 | 106 | 1294 | 8.3 (6.8, 9.8)  | 7.8 (6.3, 9.4)  | 72  | 1244 | 5.9 (4.6, 7.2) | 4.9 (3.5, 6.2) | 85  | 1023 | 8.4 (6.7, 10.1) | 7.4 (5.7, 9.1)  |
| Midwest                   | 50  | 794  | 6.3 (4.6, 8.0)  | 5.8 (4, 7.5)    | 16  | 760  | 2.1 (1.1, 3.1) | 1 (0, 2)       | 49  | 655  | 7.5 (5.5, 9.5)  | 6.5 (4.4, 8.5)  |
| South                     | 90  | 1269 | 7.2 (5.7, 8.6)  | 6.6 (5.2, 8.1)  | 31  | 1188 | 2.6 (1.8, 3.6) | 1.5 (0.7, 2.5) | 72  | 1037 | 6.9 (5.5, 8.6)  | 5.9 (4.4, 7.6)  |
| West                      | 57  | 1097 | 5.2 (3.9, 6.5)  | 4.6 (3.3, 6)    | 15  | 1038 | 1.5 (0.7, 2.2) | 0.4 (0, 1.1)   | 52  | 896  | 5.8 (4.3, 7.3)  | 4.8 (3.2, 6.3)  |
| US Dep                    | 0   | 5    | 0 (0, 0)        |                 | 0   | 5    | 0 (0, 0)       | 0 (0, 0)       | 0   | 4    | 0 (0, 0)        | 0 (0, 0)        |
| <b>Healthcare worker*</b> |     |      |                 |                 |     |      |                |                |     |      |                 |                 |
| No                        | 274 | 4042 | 6.8 (6.0, 7.6)  | 6.3 (5.4, 7.1)  | 124 | 3835 | 3 (2.2, 3.7)   | 1.9 (1.1, 2.6) | 233 | 3283 | 7.1 (6.3, 8)    | 6.1 (5.3, 7)    |
| Yes                       | 29  | 417  | 7.0 (4.5, 9.4)  | 6.5 (3.9, 8.9)  | 10  | 400  | 2.4 (0.1, 4.7) | 1.3 (0, 3.6)   | 25  | 332  | 7.5 (4.7, 10.4) | 6.5 (3.6, 9.4)  |
| <b>Essential worker</b>   |     |      |                 |                 |     |      |                |                |     |      |                 |                 |
| No                        | 257 | 3858 | 6.7 (5.9, 7.5)  | 6.2 (5.3, 7)    | 120 | 3662 | 3.3 (2.7, 3.9) | 1.9 (1.3, 2.5) | 218 | 3137 | 7 (6.1, 7.9)    | 6 (5.1, 6.9)    |
| Yes                       | 46  | 601  | 7.7 (5.5, 9.8)  | 7.2 (4.9, 9.4)  | 14  | 573  | 2.4 (1.2, 3.7) | 3.3 (1.8, 4.9) | 40  | 478  | 8.4 (5.9, 10.9) | 7.4 (4.9, 9.9)  |
| <b>High Risk group***</b> |     |      |                 |                 |     |      |                |                |     |      |                 |                 |
| No                        | 162 | 2074 | 7.8 (6.7, 9.0)  | 7.3 (6.2, 8.5)  | 79  | 1974 | 4.0 (3.1, 4.9) | 3 (2.1, 3.9)   | 136 | 1669 | 8.2 (6.8, 9.5)  | 6.9 (5.6, 8.3)  |
| Yes                       | 141 | 2385 | 6.0 (5.0, 6.9)  | 5.4 (4.4, 6.4)  | 55  | 2261 | 2.5 (1.8, 3.1) | 1.4 (0.8, 2)   | 122 | 1946 | 6.3 (5.2, 7.4)  | 5.1 (4, 6.2)    |

\*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

\*\*Adjusted for laboratory test performance

\*\*\* >60 years old, or reported co-morbidity, or current smoker.

## Table S2.

Crude and adjusted\*\* cumulative incidence estimates of SARS-CoV-2 infection in CHASING COVID Cohort Study participants by time period of testing.

Table S3. Crude and adjusted\* cumulative incidence estimates of SARS-CoV-2 infection by risk factor and timing of test in CHASING COVID Cohort Study participants

|   | All unique participants with a serologic test result<br>(Baseline or follow-up) N=4,459 |                       |  |   | Participants with a serologic test in Period 1<br>(N=4,235) |                       |  |   | Participants with a serologic test in Period 2 (N=3,615) |                       |  |   |
|---|---|-----------------------|--|---|---|-----------------------|--|---|--|-----------------------|--|---|
|   | Positive test<br>(Period 1<br>and/or<br>Period 2)                                       | Total<br>participants | Crude<br>cumulative<br>incidence<br>(95% CI) | Adjusted<br>cumulative<br>incidence<br>(95% CI) | Positive<br>test  | Total<br>participants | Crude<br>cumulative<br>incidence<br>(95% CI) | Adjusted<br>cumulative<br>incidence<br>(95% CI) | Positive<br>Test   | Total<br>Participants | Crude<br>cumulative<br>incidence<br>(95% CI) | Adjusted<br>cumulative<br>incidence<br>(95% CI) |
| <b>Total</b>                                  | <b>303</b>  | <b>4459</b>           | <b>6.8 (6.1, 7.6)</b>                        | <b>6.3 (5.5, 7.1)</b>                           | <b>134</b>  | <b>4235</b>           | <b>3.1 (2.7, 3.7)</b>                        | <b>2.5 (2.1, 3.1)</b>                           | <b>258</b>   | <b>3615</b>           | <b>7.2 (6.3, 8)</b>                          | <b>6.7 (5.8, 7.5)</b>                           |
| <b>Non-pharmaceutical interventions</b>       |   |                       |  |   |   |                       |  |   |  |                       |  |   |
| Did not use mask                              | 15  | 217                   | 6.9 (4.2, 11.1)                              | 6.4 (3.6, 10.7)                                 | 3   | 200                   | 1.5 (0.3, 4.3)                               | 0.8 (0, 3.7)                                    | 14   | 274                   | 5.1 (3.1, 8.4)                               | 4.5 (2.5, 7.9)                                  |
| Attended gatherings                           | 27  | 299                   | 9 (6.3, 12.8)                                | 8.6 (5.8, 12.4)                                 | 9   | 284                   | 3.1 (1.4, 5.9)                               | 2.5 (0.7, 5.3)                                  | 98   | 1354                  | 7.2 (5.9, 8.7)                               | 6.7 (5.3, 8.2)                                  |
| Attended Protests                             | -   | -                     | -  | -   | -   | -                     | -  | -   | 11   | 169                   | 6.5 (3.7, 11.3)                              | 6 (3.1, 10.9)                                   |
| Did not Self-Quarantine                       | 98  | 1554                  | 6.3 (5.2, 7.6)                               | 5.8 (4.6, 7.1)                                  | 28  | 1481                  | 1.9 (1.2, 2.7)                               | 1.2 (0.5, 2.1)                                  | 211  | 3552                  | 5.9 (5.2, 6.7)                               | 5.3 (4.6, 6.2)                                  |
| Decreased hand-washing                        | 6   | 96                    | 6.2 (2.9, 12.9)                              | 5.7 (2.3, 12.5)                                 | 2   | 91                    | 2.1 (0.2, 7.7)                               | 1.4 (0, 7.2)                                    | 24   | 389                   | 6.2 (4.2, 9)                                 | 5.7 (3.6, 8.5)                                  |
| <b>Household factors</b>                      |   |                       |  |   |   |                       |  |   |  |                       |  |   |
| Child in household                            | 77  | 1204                  | 6.4 (5.1, 7.9)                               | 5.9 (4.5, 7.4)                                  | 32  | 1126                  | 2.8 (2, 4)                                   | 2.2 (1.3, 3.4)                                  | 62   | 961                   | 6.4 (5.1, 8.2)                               | 5.9 (4.5, 7.7)                                  |
| Household crowding                            |   |                       |  |   |   |                       |  |   |  |                       |  |   |
| <4 persons in household                       | 222   | 3356                  | 6.6 (5.8, 7.5)                               | 6.1 (5.2, 7)                                    | 103   | 3207                  | 3.2 (2.6, 3.8)                               | 2.6 (2, 3.2)                                    | 188  | 2732                  | 6.8 (5.9, 7.9)                               | 6.2 (5.3, 7.4)                                  |
| 4+ persons in single unit                     | 56  | 834                   | 6.7 (5.2, 8.6)                               | 6.2 (4.6, 8.1)                                  | 22  | 744                   | 2.8 (1.8, 4.2)                               | 2.2 (1.1, 3.6)                                  | 48   | 671                   | 7.1 (5.4, 9.3)                               | 6.6 (4.8, 8.8)                                  |
| 4+ persons in multi unit                      | 23  | 249                   | 9.2 (6.2, 13.5)                              | 8.7 (5.7, 13.2)                                 | 9   | 236                   | 3.8 (2, 7.1)                                 | 3.2 (1.3, 6.6)                                  | 20   | 199                   | 10.1 (6.6, 15)                               | 9.7 (6.1, 14.7)                                 |
| <b>History of COVID infection and testing</b> |   |                       |  |   |   |                       |  |   |  |                       |  |   |
| Thought had COVID                             | 85  | 629                   | 13.5 (11.1, 16.4)                            | 13.2 (10.7, 16.1)                               | 58  | 604                   | 9.6 (7.5, 12.2)                              | 9.1 (7, 11.8)                                   | 95   | 675                   | 14.1 (11.6, 16.9)                            | 13.8 (11.2, 16.6)                               |
| Known COVID exposure                          | -   | -                     | -  | -   | -   | -                     | -  | -   | 27   | 205                   | 13.2 (9.2, 18.5)                             | 12.8 (8.7, 18.3)                                |
| Sought a test                                 | -   | -                     | -  | -   | -   | -                     | -  | -   | 169  | 1804                  | 9.4 (8.1, 10.8)                              | 8.9 (7.6, 10.4)                                 |
| Self-reported positive diagnosis              | -   | -                     | -  | -   | -   | -                     | -  | -   | 82   | 182                   | 45.1 (38, 52.3)                              | 45.6 (38.3, 53)                                 |
| Self-reported hospitalization                 | -   | -                     | -  | -   | -   | -                     | -  | -   | 8  | 67                    | 11.9 (6.2, 21.8)                             | 11.5 (5.7, 21.7)                                |
| Knew someone who died                         | 33  | 435                   | 7.6 (5.4, 10.5)                              | 7.1 (4.8, 10.1)                                 | 17  | 416                   | 4.1 (2.5, 6.4)                               | 3.5 (1.8, 5.9)                                  | 84   | 1213                  | 6.9 (5.6, 8.5)                               | 6.4 (5, 8)                                      |
| No Insurance                                  | 55  | 663                   | 8.3 (6.4, 10.6)                              | 7.8 (5.9, 10.2)                                 | 23  | 616                   | 3.7 (2.5, 5.5)                               | 3.1 (1.8, 4.9)                                  | 80   | 1025                  | 7.8 (6.3, 9.6)                               | 7.3 (5.8, 9.1)                                  |
| <b>Comorbidities</b>                          |   |                       |  |   |   |                       |  |   |  |                       |  |   |
| Asthma  | 42  | 745                   | 5.6 (4.2, 7.5)                               | 5 (3.6, 7)                                      | 15  | 686                   | 2.1 (1.2, 3.5)                               | 1.4 (0.5, 2.9)                                  | 35   | 745                   | 4.7 (3.4, 6.5)                               | 4.1 (2.8, 6)                                    |
| Heart attack                                  | 4   | 53                    | 7.6 (2.9, 17.8)                              | 7 (2.3, 17.6)                                   | 1   | 50                    | 1.9 (0.1, 10.4)                              | 1.2 (-0.7, 10)                                  | 3  | 53                    | 7.7 (2.6, 20.3)                              | 7.2 (2, 20.1)                                   |

|                                       |     |      |                  |                 |    |      |                |                |     |      |                  |                 |
|---------------------------------------|-----|------|------------------|-----------------|----|------|----------------|----------------|-----|------|------------------|-----------------|
| Immunosuppression                     | 3   | 135  | 2.2 (0.7, 6.3)   | 1.6 (0, 5.8)    | 2  | 129  | 1.5 (0.2, 5.4) | 0.8 (0, 4.8)   | 3   | 135  | 2.8 (0.9, 7.8)   | 2.1 (0.2, 7.3)  |
| Depression                            | 61  | 1056 | 5.7 (4.5, 7.3)   | 5.1 (3.9, 6.8)  | 16 | 995  | 1.6 (0.9, 2.5) | 0.9 (0.2, 1.8) | 55  | 1056 | 5.2 (4, 6.7)     | 4.6 (3.4, 6.2)  |
| Diabetes                              | 24  | 307  | 7.8 (5.3, 11.4)  | 7.3 (4.7, 11)   | 5  | 286  | 1.7 (0.5, 3.9) | 1 (-0.2, 3.3)  | 24  | 307  | 7.8 (5.3, 11.4)  | 7.3 (4.7, 11)   |
| HIV                                   | 20  | 214  | 9.3 (6.1, 13.9)  | 8.8 (5.5, 13.6) | 7  | 192  | 3.5 (1.4, 7.1) | 2.9 (0.7, 6.6) | 17  | 214  | 7.9 (5.1, 12.4)  | 7.4 (4.5, 12)   |
| <b>Other potential risk factors</b>   |     |      |                  |                 |    |      |                |                |     |      |                  |                 |
| Alcohol use**                         | 26  | 253  | 10.3 (7.1, 14.6) | 9.9 (6.6, 14.3) | 9  | 233  | 3.7 (1.7, 6.9) | 3.1 (1, 6.4)   | 26  | 340  | 7.6 (5.2, 10.9)  | 7.1 (4.6, 10.5) |
| Substance use***                      | -   | -    | -                | -               | -  | -    | -              | -              | 37  | 607  | 6.1 (4.4, 8.3)   | 5.5 (3.8, 7.8)  |
| Received Flu vaccine in 2019          | 136 | 1824 | 7.4 (6.3, 8.7)   | 6.9 (5.8, 8.2)  | 70 | 1751 | 4 (3.1, 5)     | 3.4 (2.5, 4.4) | 114 | 1824 | 7.4 (6.1, 8.8)   | 6.9 (5.5, 8.3)  |
| PrEP for HIV prevention               | -   | -    | -                | -               | -  | -    | -              | -              | 40  | 383  | 10.4 (7.7, 13.9) | 10 (7.2, 13.6)  |
| Pets in home                          | -   | -    | -                | -               | -  | -    | -              | -              | 78  | 1382 | 5.6 (4.5, 7)     | 5 (3.9, 6.5)    |
| Public transportation                 | 25  | 276  | 9.1 (6.2, 13)    | 8.6 (5.7, 12.6) | 11 | 258  | 4.2 (2.1, 7.5) | 3.6 (1.4, 7)   | 87  | 1053 | 8.3 (6.7, 10.1)  | 7.8 (6.2, 9.7)  |
| History of air travel during pandemic | -   | -    | -                | -               | -  | -    | -              | -              | 56  | 701  | 7.9 (6.2, 10.2)  | 7.4 (5.7, 9.8)  |

**Table S3.**

Crude and adjusted\* cumulative incidence estimates of SARS-CoV-2 infection by risk factor and timing of test in CHASING COVID Cohort Study participants



Table S4. Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by sociodemographic characteristics among CHASING COVID Cohort participants

|                           | No. of seronegative participants in Period 1 | No. of incident infections | Total PY*** of follow up | Incidence rate per 100 PY*** (95% CI) | Rate Ratio (95% CI)      |
|---------------------------|--|----------------------------|--------------------------|---------------------------------------|--------------------------|
| <b>Total</b>              | 3280   | 145                        | 1562.0                   | 9.3 (7.9, 11.0)                       | -                        |
| <b>Age group*</b>         |  |                            |                          |                                       |                          |
| 18-29                     | 584  | 33                         | 280.5                    | 11.8 (8.3, 16.7)                      | 1.26 (0.79, 2)           |
| 30-39                     | 902  | 40                         | 428.8                    | 9.3 (6.8, 12.8)                       | -ref-                    |
| 40-49                     | 626  | 31                         | 294.7                    | 10.5 (7.3, 15.1)                      | 1.13 (0.7, 1.8)          |
| 50-59                     | 494  | 20                         | 237.1                    | 8.4 (5.4, 13.2)                       | 0.9 (0.52, 1.54)         |
| 60+                       | 674  | 21                         | 320.8                    | 6.5 (4.2, 10.1)                       | 0.7 (0.41, 1.18)         |
| <b>Gender</b>             |  |                            |                          |                                       |                          |
| Male                      | 1453   | 77                         | 711.6                    | 10.8 (8.6, 13.6)                      | 1.34 (0.96, 1.87)        |
| Female                    | 1734   | 65                         | 803.2                    | 8.1 (6.3, 10.4)                       | -ref-                    |
| Non-binary/Trans          | 93   | 3                          | 43.1                     | 7.0 (2.2, 22.0)                       | 0.86 (0.21, 2.43)        |
| <b>Race/Ethnicity*</b>    |  |                            |                          |                                       |                          |
| White                     | 2218   | 83                         | 1085.4                   | 7.6 (6.1, 9.5)                        | -ref-                    |
| Hispanic                  | 485  | 34                         | 210.9                    | 16.1 (11.4, 22.8)                     | <b>2.11 (1.4, 3.12)</b>  |
| Black                     | 249  | 15                         | 109.5                    | 13.7 (8.1, 23.1)                      | 1.79 (0.96, 3.13)        |
| Asian                     | 199  | 7                          | 94.6                     | 7.4 (3.5, 13.7)                       | 0.97 (0.41, 1.99)        |
| Pacific Islander          | 15   | 0                          | 7.0                      | -                                     |                          |
| Other                     | 114  | 6                          | 54.6                     | 11.0 (4.8, 25.0)                      | 1.44 (0.57, 3.1)         |
| <b>Education</b>          |  |                            |                          |                                       |                          |
| Less than HS              | 37   | 2                          | 16.1                     | 12.4 (3.0, 51.7)                      | 1.47 (0.24, 4.98)        |
| HS grad                   | 268  | 13                         | 115.2                    | 11.3 (6.5, 19.7)                      | 1.34 (0.72, 2.33)        |
| Some college              | 774  | 39                         | 353.0                    | 11.0 (8.0, 15.2)                      | 1.31 (0.89, 1.89)        |
| Collge grad               | 2201   | 91                         | 1077.6                   | 8.4 (6.8, 10.4)                       | -ref-                    |
| <b>Employment*</b>        |  |                            |                          |                                       |                          |
| Employed                  | 2005   | 96                         | 963.3                    | 10.0 (8.1, 12.2)                      | -ref-                    |
| Out of work               | 387  | 17                         | 179.5                    | 9.5 (5.8, 15.4)                       | 0.95 (0.55, 1.56)        |
| Homemaker                 | 176  | 6                          | 77.2                     | 7.8 (3.4, 17.6)                       | 0.78 (0.31, 1.67)        |
| Student                   | 244  | 12                         | 120.1                    | 10.0 (5.6, 17.9)                      | 1 (0.53, 1.78)           |
| Retired                   | 468  | 14                         | 221.9                    | 6.3 (3.7, 10.7)                       | 0.63 (0.35, 1.08)        |
| <b>Household income*</b>  |  |                            |                          |                                       |                          |
| Less than \$35,000        | 909  | 45                         | 418.7                    | 10.7 (8.0, 14.5)                      | 1.44 (0.93, 2.26)        |
| \$35-49,999               | 361  | 19                         | 168.8                    | 11.3 (7.1, 17.9)                      | 1.51 (0.85, 2.63)        |
| \$50-69,999               | 484  | 16                         | 229.3                    | 7.0 (4.2, 11.5)                       | 0.94 (0.51, 1.68)        |
| \$70-99,999               | 574  | 30                         | 275.7                    | 10.9 (7.5, 15.7)                      | 1.46 (0.89, 2.38)        |
| \$100,000+                | 952  | 35                         | 469.5                    | 7.5 (5.3, 10.4)                       | -ref-                    |
| <b>Setting*</b>           |  |                            |                          |                                       |                          |
| Urban                     | 1426   | 54                         | 693.6                    | 7.9 (5.9, 10.2)                       | -ref-                    |
| Suburban                  | 846  | 36                         | 404.3                    | 8.9 (6.4, 12.4)                       | 1.14 (0.74, 1.74)        |
| Rural                     | 1008   | 55                         | 464.1                    | 11.9 (9.0, 15.6)                      | <b>1.52 (1.04, 2.22)</b> |
| <b>Geographic region*</b> |  |                            |                          |                                       |                          |
| Northeast                 | 910  | 30                         | 447.6                    | 6.7 (4.7, 9.6)                        | -ref-                    |

|                           |      |     |        |                  |                          |
|---------------------------|------|-----|--------|------------------|--------------------------|
| Midwest                   | 605  | 31  | 285.8  | 10.8 (7.6, 15.6) | 1.62 (0.98, 2.69)        |
| South                     | 934  | 50  | 431.5  | 11.5 (8.7, 15.4) | <b>1.73 (1.1, 2.75)</b>  |
| West                      | 827  | 34  | 394.0  | 8.6 (6.1, 12.2)  | 1.29 (0.79, 2.12)        |
| US Dep                    | 4    | 0   | 2.0    | 0 (, )           | 0 (0, 11.75)             |
| <b>Healthcare worker*</b> |      |     |        |                  |                          |
| No                        | 2973 | 129 | 1416.1 | 9.1 (7.6, 10.9)  | -ref-                    |
| Yes                       | 307  | 16  | 145.8  | 11.0 (6.6, 18.1) | 1.2 (0.69, 1.98)         |
| <b>Essential worker</b>   |      |     |        |                  |                          |
| No                        | 2842 | 116 | 1356.8 | 8.5 (7.1, 10.3)  | -ref-                    |
| Yes                       | 438  | 29  | 205.1  | 14.1 (9.7, 20.6) | <b>1.65 (1.09, 2.46)</b> |
| <b>High Risk group**</b>  |      |     |        |                  |                          |
| No                        | 1506 | 72  | 722.5  | 10.0 (7.9, 12.6) | -ref-                    |
| Yes                       | 1774 | 73  | 839.5  | 8.7 (6.9, 11.0)  | 0.87 (0.63, 1.21)        |

\*<5% of the data were missing for this variable and values for those with missing values were imputed by assigning the most common value for this variable

\*\*>60 years old, or reported co-morbidity, or current smoker.

\*\*\*PY = Person Years

#### **Table S4.**

Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by sociodemographic characteristics among CHASING COVID Cohort participants

Table S5. Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by risk factor among CHASING COVID Cohort participants

|                                       | No. of seronegative participants in Period 1 | No. of incident infections | Total PY of follow up | Incidence rate per 100 PY (95% CI) | Rate Ratio (95% CI)      |
|---------------------------------------|--|----------------------------|-----------------------|------------------------------------|--------------------------|
| <b>Total</b>                          | 3280   | 145                        | 1562                  | 9.3 (7.9, 10.8)                    |                          |
| <b>Household factors</b>              |  |                            |                       |                                    |                          |
| Household crowding                    | 785  | 35                         | 259.38                | 13.5 (9.8, 18.1)                   | <b>1.61 (1.08, 2.32)</b> |
| No household crowding                 | 2495   | 110                        | 1302.62               | 8.4 (7.1, 10.1)                    | -ref-                    |
| Child in household                    | 932  | 40                         | 421.65                | 9.5 (7, 12.6)                      | 1.03 (0.71, 1.47)        |
| No child in household                 | 2348   | 105                        | 1140.37               | 9.2 (7.6, 11)                      | -ref-                    |
| No Confirmed case in household member | 42   | 18                         | 34.14                 | 0.5 (0.32, 0.81)                   | -ref-                    |
| Confirmed case in household member    | 82   | 25                         | 14.73                 | 1.7 (1.1, 2.5)                     | 3.2 (1.7, 6)             |
| NA                                    | 3156   | 102                        | 1513.15               | 0.1 (0.05, 0.08)                   |                          |
| <b>Social distancing</b>              |  |                            |                       |                                    |                          |
| Attended mass gathering(s)            | 337  | 16                         | 167.26                | 9.5 (5.9, 14.9)                    | 1.03 (0.6, 1.7)          |
| Did not attend mass gathering(s)      | 2943   | 129                        | 1394.76               | 9.2 (7.8, 10.8)                    | -ref-                    |
| Indoor dining/bar                     | 1787   | 102                        | 854.15                | 11.9 (9.9, 14.3)                   | <b>1.95 (1.38, 2.83)</b> |
| No indoor dining/bar                  | 1489   | 43                         | 707.86                | 6.1 (4.5, 8.1)                     | -ref-                    |
| Outdoor dining/bar                    | 1896   | 92                         | 928.21                | 9.7 (7.8, 11.8)                    | 1.15 (0.85, 1.67)        |
| No outdoor dining/bar                 | 1384   | 53                         | 633.8                 | 8.4 (6.4, 10.7)                    | -ref-                    |
| Visited place of worship              | 341  | 26                         | 158                   | 16.4 (11.5, 21)                    | <b>1.95 (1.25, 2.93)</b> |
| Did not visit place of worship        | 2939   | 119                        | 1404.02               | 8.4 (7.1, 10)                      | -ref-                    |

|   |      |     |         |                   |                          |
|---|------|-----|---------|-------------------|--------------------------|
| Visited public park/public pool                   | 2323 | 103 | 1131.22 | 9.1 (7.5, 10.9)   | 0.94 (0.66, 1.35)        |
| Did not visit public park/pool                    | 957  | 42  | 430.8   | 9.7 (7.3, 12.9)   | -ref-                    |
| <b>Mask indoor grocery shopping</b>               |      |     |         |                   |                          |
| N/A (Did not go grocery shopping)                 | 161  | 8   | 77.77   | 10.3 (5.3, 19)    | 1.17 (0.53, 2.27)        |
| Always  | 2959 | 125 | 1415.05 | 8.8 (7.4, 10.4)   | -ref-                    |
| Sometimes   | 128  | 12  | 54.73   | 21.9 (13, 21.5)   | <b>2.49 (1.31, 4.36)</b> |
| Never   | 32   | 0   | 14.47   | 0 (0, 20.9)       | 0 (0, 2.37)              |
| <b>Mask indoor visiting non-household members</b> |      |     |         |                   |                          |
| N/A (Did no visit non-household members indoors)  | 666  | 27  | 688.8   | 3.9 (4.7, 5.6)    | -ref-                    |
| Always  | 1047 | 37  | 358.54  | 10.3 (7.5, 13.9)  | <b>2.64 (1.6, 4.37)</b>  |
| Sometimes   | 1081 | 51  | 369     | 13.8 (10.7, 17.7) | <b>3.54 (2.22, 5.69)</b> |
| Never   | 438  | 30  | 145.66  | 20.6 (14.8, 27.8) | <b>5.28 (3.11, 8.9)</b>  |
| <b>Mask indoor at work</b>                        |      |     |         |                   |                          |
| N/A (Did not attend indoor workplace)             | 1595 | 68  | 1005.17 | 6.7 (5.3, 8.4)    | -ref-                    |
| Always  | 1293 | 59  | 439.83  | 13.4 (10.5, 16.9) | <b>2 (1.4, 2.81)</b>     |
| Sometimes   | 282  | 13  | 96.81   | 13.4 (8, 21.6)    | <b>2 (1.06, 3.51)</b>    |
| Never   | 61   | 5   | 20.19   | 24.7 (11.1, 46.5) | <b>3.69 (1.3, 8.46)</b>  |
| <b>Mask indoor at salon/gym</b>                   |      |     |         |                   |                          |
| N/A (Did not attend salon/gym)                    | 2426 | 106 | 1290.06 | 8.2 (6.8, 9.8)    | -ref-                    |
| Always  | 699  | 32  | 237.52  | 13.5 (9.7, 18.4)  | <b>1.65 (1.09, 2.41)</b> |
| Sometimes   | 31   | 3   | 9.91    | 30.3 (10.8, 60.7) | 3.7 (0.92, 10.26)        |
| Never   | 75   | 4   | 24.51   | 16.3 (6.5, 35.2)  | 1.99 (0.62, 4.91)        |
| <b>Outdoor mask use</b>                           |      |     |         |                   |                          |
| Mask use outdoors                                 | 1501 | 65  | 716.41  | 9.1 (7.2, 11.4)   | 0.96 (0.69, 1.33)        |
| No mask use outdoors                              | 1779 | 80  | 845.61  | 9.5 (7.6, 11.6)   | -ref-                    |
| <b>Gathered outside in groups &gt;=10</b>         |      |     |         |                   |                          |
| No  | 1897 | 66  | 898.78  | 7.3 (5.8, 9.2)    | -ref-                    |
| Indoors only                                      | 224  | 11  | 104.58  | 10.5 (6, 17.8)    | 1.43 (0.72, 2.64)        |
| Outdoors only                                     | 661  | 35  | 322.47  | 10.9 (7.9, 14.7)  | 1.48 (0.97, 2.22)        |
| Indoors and outdoors                              | 498  | 33  | 236.19  | 14 (10.1, 19)     | <b>1.9 (1.24, 2.88)</b>  |
| <b>Movement during the pandemic</b>               |      |     |         |                   |                          |
| <b>Recent use of public transit</b>               |      |     |         |                   |                          |
| Avoided or did not use                            | 2628 | 113 | 1251.33 | 9 (7.5, 10.7)     | -ref-                    |
| Did not avoid                                     | 652  | 32  | 310.69  | 10.3 (7.3, 14.2)  | 1.14 (0.76, 1.67)        |
| <b>Recent Air travel (Aug-Nov)</b>                |      |     |         |                   |                          |

|     |      |     |         |                   |                          |
|-----|------|-----|---------|-------------------|--------------------------|
| Yes | 410  | 29  | 199.11  | 14.6 (10.2, 20.1) | <b>1.72 (1.12, 2.55)</b> |
| No  | 2870 | 116 | 1362.91 | 8.5 (7.1, 10.1)   | -ref-                    |

**Table S5.**

Incidence rates of recent SARS-CoV-2 seroconversion (May 2020-January 2021) by risk factor among CHASING COVID Cohort participants

Table S6. Characteristics of persons with seroprevalent and seroincident SARS-CoV-2

|   | All seropositive persons |      | Observed seroconverters (seronegative in Period 1 and seropositive in Period 2) |      | Prevalent cases (seropositive on first antibody test) |      | Seroreversions (seropositive in Period 1, seronegative in Period 2) |      |
|---|--------------------------|------|---|------|---|------|---|------|
|   | N                        | %    | N   | %    | N   | %    | N   | %    |
| <b>Total</b>  | 303                      | 100  | 145   | 47.9 | 138   | 45.5 | 20.0  | 6.6  |
| <b>Symptoms and clinical outcomes</b>                       |                          |      |   |      |   |      |   |      |
| Aware of past SARS-CoV-2 infection (footnote)               | 121                      | 39.9 | 35  | 24.1 | 74  | 53.6 | 12.0  | 60.0 |
| PCR confirmed diagnosis                                     | 89                       | 29.4 | 42  | 29.0 | 41  | 29.7 | 6.0   | 30.0 |
| Asymptomatic (footnote details)                             | 83                       | 27.4 | 37  | 25.5 | 39  | 28.3 | 7.0   | 35.0 |
| Mild (symptomatic, but didn't seek care)                    | 190                      | 62.7 | 87  | 60.0 | 87  | 63.0 | 16.0  | 80.0 |
| History of COVID like illness at baseline*                  | 121                      | 39.9 | 51  | 35.2 | 62  | 44.9 | 8.0   | 40.0 |
| Ever had COVID like illness*                                | 209                      | 69.0 | 105   | 72.4 | 93  | 67.4 | 11.0  | 55.0 |
| Nasal discharge, congestion or sneezing                     | 225                      | 74.3 | 107   | 73.8 | 103   | 74.6 | 15.0  | 75.0 |
| Cough/Cough up phlegm                                       | 158                      | 52.2 | 77  | 53.1 | 70  | 50.7 | 11.0  | 55.0 |
| Cough up blood  | 2                        | 0.7  | 1   | 0.7  | 0   | 0.0  | 1.0   | 5.0  |
| Sore throat   | 140                      | 46.2 | 71  | 49.0 | 61  | 44.2 | 8.0   | 40.0 |
| Itchy eye or eye pain                                       | 114                      | 37.6 | 58  | 40.0 | 48  | 34.8 | 8.0   | 40.0 |
| Shortness of breath or chest pain                           | 91                       | 30.0 | 37  | 25.5 | 49  | 35.5 | 5.0   | 25.0 |
| Stomachache, diarrhea, nausea or vomiting                   | 142                      | 46.9 | 64  | 44.1 | 69  | 50.0 | 9.0   | 45.0 |
| Rash  | 25                       | 8.3  | 12  | 8.3  | 10  | 7.3  | 3.0   | 15.0 |
| Loss of smell   | 61                       | 20.1 | 30  | 20.7 | 28  | 20.3 | 3.0   | 15.0 |
| Headache  | 202                      | 66.7 | 93  | 64.1 | 97  | 70.3 | 12.0  | 60.0 |
| Fever, chills or repeated chills                            | 120                      | 39.6 | 50  | 34.5 | 61  | 44.2 | 9.0   | 45.0 |
| Myalgia   | 106                      | 35.0 | 58  | 40.0 | 45  | 32.6 | 3.0   | 15.0 |
| Ever hospitalized   | 10                       | 3.3  | 3   | 2.1  | 7   | 5.1  | 0.0   | 0.0  |
| <b>Public health outcomes and testing history</b>           |                          |      |   |      |   |      |   |      |
| Ever tested for COVID                                       | 195                      | 64.4 | 92  | 63.5 | 91  | 65.9 | 12  | 60.0 |
| Positive SARS-CoV-2 PCR test                                | 97                       | 32.0 | 43  | 29.7 | 48  | 34.8 | 6.0   | 30.0 |
| Isolated from people outside household                      | 93                       | 30.7 | 42  | 29.0 | 45  | 32.6 | 6   | 30.0 |
| Isolated from people within household                       | 41                       | 13.5 | 23  | 15.9 | 16  | 11.6 | 2   | 10.0 |
| Quarantined after contact with COVID                        | 30                       | 9.9  | 23  | 15.9 | 6   | 4.3  | 1   | 5.0  |
| Asked about contacts after COVID diagnosis                  | 54                       | 17.8 | 29  | 20.0 | 24  | 17.4 | 1   | 5.0  |
| Told about contacts with COVID case                         | 23                       | 7.6  | 10  | 6.9  | 8   | 5.8  | 5   | 25.0 |
| Encouraged to get tested because of contact with COVID case | 12                       | 4.0  | 6   | 4.1  | 2   | 1.4  | 4   | 20.0 |
| Told to stay home for a period of time                      | 10                       | 3.3  | 4   | 2.8  | 4   | 2.9  | 2   | 10.0 |

---

\*based on CTSE case definition

**Table S6.**

Characteristics of persons with seroprevalent and seroincident SARS-CoV-2



Table S7. Additional serologic testing for antibodies to the SARS-CoV-2 spike protein in 392 samples\* that were seropositive for antibodies to the SARS-CoV-2 nucleocapsid protein

|                              | Specimens positive by Total Ab in Period 1 or Period 2 |       | Individuals positive by Total Ab in Period 1 |       | Individuals positive by Total Ab in Period 2 |       | Seroconverters (seropositive by Total AB in Period 1, seronegative by Total AB in Period 2) |       | Seroreverters (seropositive by Total AB in Period 1, seronegative by Total AB in Period 2) |       |
|------------------------------|--|-------|--|-------|--|-------|---|-------|--|-------|
|                              | N  | %     | N  | %     | N  | %     | N   | %     | N  | %     |
| <b>Total</b>                 | 392  | 100%  | 134  | 100%  | 258  | 100%  | 145   | 100%  | 20   | 100.0 |
| <b>Spike IgG result</b>      |  |       |  |       |  |       |   |       |  |       |
| Equivocal                    | 28   | 7.1%  | 8  | 6.0%  | 20   | 7.8%  | 6   | 4.1%  | 2  | 10.0% |
| Non-Reactive                 | 132  | 33.7% | 31   | 23.1% | 101  | 39.1% | 64  | 44.1% | 13   | 65.0% |
| Quantity Not Sufficient      | 31   | 7.9%  | 7  | 5.2%  | 24   | 9.3%  | 14  | 9.7%  | 0  | 0.0%  |
| Reactive                     | 201  | 51.3% | 88   | 65.7% | 113  | 43.8% | 61  | 42.1% | 5  | 25.0% |
| % reactive (excluding QNS**) |  | 63.4% |  | 75.6% |  | 56.8% |   | 51.1% |  | 35.0% |

\*392 seropositive samples from 303 seropositive participants

\*\*Quantity not sufficient for serologic testing

**Table S7.**

Additional serologic testing for antibodies to the SARS-CoV-2 spike protein in 392 samples\* that were seropositive for antibodies to the SARS-CoV-2 nucleocapsid protein